

CURRICULUM VITAE
JU NYEONG PARK, Ph.D., M.H.S.

Business

Rhode Island Hospital, Brown University Health
593 Eddy Street
Providence, RI 02903-4923
Office telephone: (401) 212-4730
Fax: (401) 793-4779
Email: jpark14@brownhealth.org |
ju_park@brown.edu

Office

Harm Reduction Innovation Lab
1125 N. Main St, Suite 207
Providence, RI 02906
Cell phone: (202) 386-2834
Faculty profile: <https://vivo.brown.edu/display/jpark348>
Lab website: www.harmreductionlab.com

EDUCATION

Undergraduate

University of Sydney
Neuroscience & Physiology
Bachelor of Science (Hons), 2009

Other Advanced Degrees

The Johns Hopkins University
Epidemiology
Master of Health Science, 2013

The Johns Hopkins University
Epidemiology
Doctor of Philosophy, 2018

POSTGRADUATE HONORS AND AWARDS

- | | |
|------|--|
| 2025 | Highly Ranked Scholar (1st) - Prior Five Years in the Specialty of Fentanyl, ScholarGPS |
| 2024 | Drug Policy Evaluation Award (co-recipient), International Society for the Study of Drug Policy |
| 2024 | Highly Ranked Scholar (2nd) - Prior Five Years in the Specialty of Fentanyl, ScholarGPS |
| 2023 | AMERSA Conference Travel Award |
| 2019 | NIDA Women & Sex/Gender Differences Junior Investigator Travel Award |
| 2016 | Charlotte Silverman Award, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health |
| 2014 | 10 th National Harm Reduction Conference Scholarship, New York, NY |
| 2013 | International AIDS Society Conference Scholarship, Geneva, Switzerland |
| 2013 | Center for Global Health Conference Travel Grant, Johns Hopkins University |

- 2013 Anna Huffstutler Stiles Scholarship, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health
- 2013 Community Service Award, Johns Hopkins Student Outreach Resource Center

ACADEMIC APPOINTMENTS

- 2024- Faculty Affiliate, Center for Alcohol and Addiction Studies (CAAS), Brown University, Providence, RI
- 2021- Assistant Professor (Research), Division of General Internal Medicine (primary), The Warren Alpert Medical School, Brown University, Providence, RI
- 2021- Assistant Professor (Research), Department of Epidemiology (secondary), School of Public Health, Brown University, Providence, RI
- 2021 Associate Scientist, Department of Health, Behavior and Society, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
- 2018-2021 Assistant Scientist, Department of Health, Behavior and Society, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD

HOSPITAL APPOINTMENTS

- 2021- Research Scientist, Division of General Internal Medicine, Department of Medicine, Rhode Island Hospital, Providence, RI

OTHER APPOINTMENTS

- 2025 Consultant, Engaging Overdose Survivors with the SafeSpot Hotline for Secondary Overdose Prevention (PI: Walley). Boston Medical Center, Boston, MA
- 2025 Brown Physicians Inc Grant Reviewer
- 2024- Member, Data Safety Monitoring Board, Drexel University (PI: Lankenau)
- 2024- Editorial Advisory Board, Social Science & Medicine
- 2024- Brown General Internal Medicine Residency Abstract Review Committee
- 2023- Co-Director, Research Track, Brown Internal Medicine Residency Program
- 2023- Editorial Board, International Journal of Drug Policy
- 2023- NIH HEAL Sleep and Opioid Use Disorder National Steering Committee
- 2023- Rhode Island State Epidemiological Outcomes Workgroup

2023 Conference Planning Committee, Alliance for Collaborative Drug Checking

2021- Abstract reviewer, Symposium on Substance Use Research, University of Nebraska-Lincoln

2021-2023 Consultant, Enhancing FDA's opioids systems modeling efforts to more comprehensively address fentanyl, stimulants, polysubstance use, and associated outcomes (PI: Jalali). Harvard Medical School, Massachusetts General Hospital

2019-2020 Consultant, Technical Advisor to the Maryland Opioid Operational Command Center (OCCC), Bloomberg American Health Initiative, Johns Hopkins Bloomberg School of Public Health

2018-2019 Consultant, Delaware Fentanyl Test Strip Program Evaluation, Delaware Department of Health and Social Services. Bloomberg American Health Initiative, Johns Hopkins Bloomberg School of Public Health

2017-2018 Study Director, FORECAST Study (MPIs: Sherman/Green). Johns Hopkins Bloomberg School of Public Health

2016-2017 Project Coordinator, Baltimore Syringe Exchange Program Study (PI: Sherman), Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health

2015-2018 Data Analyst, SAPPHIRE Study (PI: Sherman), Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health

2015-2016 Consultant, Needs-Assessment for Responding to Public Health Emergencies. World Health Organization, Geneva, Switzerland

2013-2016 Data Manager, BESURE Study, Baltimore NHBS-CDC (MPI: German/Flynn), Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health

2013-2014 Consultant, Enhancing Provider-Initiated HIV Testing in Sydney project. Kirby Institute, University of New South Wales, Sydney, Australia

2012-2013 Graduate Research Assistant, ALIVE Study (PI: Mehta), Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health

2012 HIV/AIDS Research Intern, USAID HIV Epidemiology Study (PI: Baral), Johns Hopkins Center for Global Health, Yaoundé, Cameroon

2011 Graduate Research Assistant, Systematic Review team. Center for Public Health and Human Rights (PI: Beyrer), Johns Hopkins Bloomberg School of Public Health

2010-2011 Research Assistant, HITS-C Study (PI: Maher), Kirby Institute, University of New South Wales, Sydney, Australia

UNIVERSITY COMMITTEES

- 2023- Research Track Co-Director, Brown Internal Medicine Residency Program, Warren Alpert Medical School, Brown University, Providence, RI
- 2020-2021 Executive Committee, Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 2020-2021 Communications Advisory Committee, Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 2016-2018 Doctoral Student Council, Student Assembly, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 2015-2016 President (joint), Epidemiology Student Organization, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 2013-2014 Community Advisory Board, Center for AIDS Research, Johns Hopkins University, Baltimore, MD

MEMBERSHIP IN SOCIETIES

- 2024- College on Problems of Drug Dependence
- 2024- AMERSA
- 2022 American Public Health Association
- 2021- Maryland Public Health Association
- 2017 Society for Epidemiologic Research
- 2013-2018 International AIDS Society
- 2011 Australian Society for HIV Medicine (ASHM)

EDITORIAL ACTIVITIES

Peer Reviewer

- 2020- Addiction
- 2021- Addiction Research and Theory
- 2017-2018 AIDS and Behavior
- 2017 AIDS Care
- 2020- American Journal of Drug and Alcohol Abuse
- 2023- American Journal of Psychiatry
- 2024- American Journal of Public Health
- 2023- BMC Public Health
- 2018- Drug and Alcohol Dependence
- 2021- Drug and Alcohol Review

2022- Epidemiology
 2017- Harm Reduction Journal
 2018- International Journal of Drug Policy
 2024- JAMA Network Open
 2017 Journal of the International AIDS Society
 2023- Journal of Urban Health
 2021- Lancet Psychiatry
 2020- Lancet Public Health
 2022- Lancet Regional Health - Americas
 2026- Nature Communications
 2019- PLOS ONE
 2024- Social Psychiatry and Psychiatric Epidemiology
 2024- Social Science & Medicine
 2020- Substance Abuse Treatment, Prevention, and Policy
 2023- Substance Use and Misuse

PUBLICATIONS LIST

ORIGINAL PUBLICATIONS IN PEER REVIEWED JOURNALS (*MENTEES)

1. **Park JN**, White B, Bates A, Enriquez J, Liao L, Maher L. Motivators and barriers influencing willingness to participate in candidate HCV vaccine trials: Perspectives of people who inject drugs. *Drug and Alcohol Dependence*. 2012; 123(1-3):35-40.
2. **Park JN**, Papworth E, Kassegne S, Moukam L, Billong SC, Macauley I, Yomb YR, Nkoume N, Mondoleba V, Eloundou J, LeBreton M, Tamoufe U, Grosso A, Baral S. HIV prevalence and factors associated with HIV infection among men who have sex with men in Cameroon. *J International AIDS Society*. 2013; 16 Suppl 3:18752.
3. **Park JN**, Papworth E, Billong SC, Elat JB, Kassegne S, Grosso A, Moukam L, Macauley L, Yomb YR, Mondoleba V, Eloundou J, LeBreton M, Ketende SC, Baral S. Correlates of prior HIV testing among men who have sex with men in Cameroon: a cross-sectional analysis. *BMC Public Health*. 2014; 14:1220.
4. Lewis DA, **Park JN**, Vail L, Sine M, Welsh C, Sherman SG. Evaluation of the overdose education and naloxone distribution program of the Baltimore Student Harm Reduction Coalition. *American Journal of Public Health*. 2016; 106(7):1243-6.
5. Maragh-Bass AC, Powell C, **Park JN**, Flynn C, German D. Sociodemographic and access-related correlates of health-care utilization among African American injection drug users: The BESURE study. *J Ethn Subst Abuse*. 2016; 16(3):344-362.
6. Fallon SA, **Park JN**, Ogbue CP, Flynn C, German D. Awareness and acceptability of pre-exposure HIV prophylaxis among men who have sex with men in Baltimore. *AIDS and Behavior*. 2017; 21(5):1268-1277.

7. German D, Brady K, Kuo I, Opoku J, Flynn C, Patrick R, **Park JN**, Adams J, Carroll M, Simmons R, Smith CR, Davis W On Behalf of the Mid-Atlantic CFAR Consortium. Characteristics of black men who have sex with men in Baltimore, Philadelphia, and Washington, D.C.: Geographic diversity in socio-demographics and HIV transmission risk. *J Acquir Immune Defic Syndr*. 2017; 75 (Suppl 3):S296-S308.
8. Sherman, SG, Hast, M, **Park JN**, Decker, MR., Flynn C., German D. Correlates of exchange sex among a population-based sample of low-income women who have heterosexual sex in Baltimore. *AIDS Care*. 2018; 30(10):1273-1281.
9. **Park JN**, Weir B, Allen, ST, Chaulk P, Sherman SG. Fentanyl-contaminated drugs and non-fatal overdose among people who inject drugs in Baltimore, MD. *Harm Reduction Journal*. 2018; 15(1):1-8.
10. Hunter K, **Park JN**, Allen ST, Chaulk P, Frost T, Weir BW, Sherman SG. Safe and unsafe spaces: Non-fatal overdose, arrest, and receptive syringe sharing among public and semi-public injectors in Baltimore City. *International Journal of Drug Policy*. 2018; 57:25-31.
11. Allen ST, Footer KHA, Galai N, **Park JN**, Silberzahn B, Sherman SG. Implementing Targeted Sampling: Lessons Learned from Recruiting Female Sex Workers in Baltimore, MD. *Journal of Urban Health*. 2018; 96(3):442-451.
12. Footer KHA, **Park JN**, Allen ST, Decker MR, Silberzahn BE, Huettner S, Galai N, Sherman SG. Police related correlates of client violence among female sex workers in Baltimore City, Maryland, USA. *American Journal of Public Health*. 2019; 109(2):289-295.
13. Tomko C, **Park JN**, Allen ST, Glick J, Galai N, Decker MR, Footer KF, Sherman SG. Awareness and interest in HIV pre-exposure prophylaxis (PrEP) among street-based female sex workers: Results from a US context. *AIDS Patient Care and STDs*. 2019; 33(2):49-57.
14. Glick JL, Christensen T, **Park JN**, McKenzie M, Green TC, Sherman SG. Stakeholder perspectives on implementing fentanyl drug checking: Results from a multi-site study. *Drug and Alcohol Dependence*. 2019; 194:527-532.
15. Sherman SG, Schneider KE, **Park JN**, Allen ST, Hunt, D., Chaulk P, Weir BW. PrEP awareness, eligibility and interest among people who inject drugs in Baltimore, Maryland. *Drug and Alcohol Dependence*. 2019; 195:148-155.
16. Rouhani S, Gudlavalleti R, Atzmon D, **Park JN**, Olsen SP, Sherman SG. Police attitudes towards pre-booking diversion in Baltimore City: the role of experience in taking a public health approach to law enforcement. *International Journal of Drug Policy*. 2019; 65:78-85.
17. **Park JN**, Linton SL, Sherman, SG, German D. Police violence among people who inject drugs in Baltimore, Maryland. *International Journal of Drug Policy*. 2019; 64: 54-61.
18. Coupland H, White B, Bates A, **Park JN**, Iversen J, Maher L. Engaging people who inject drugs in hepatitis C virus testing and prevention through community-based outreach, in Sydney, Australia. *Drug and Alcohol Review*. 2019; 38(2):177-184.
19. Sherman SG, **Park JN**, Galai N, Allen ST, Huettner S, Silberzahn B, Decker MR, Poteat TC, Footer KHA. Drivers of HIV infection among cisgender and transgender female sex worker

populations in Baltimore city: Results from the SAPPHERE study. *J Acquir Immune Defic Syndr*, 2019; 80(5):513-521.

20. **Park JN**, Footer KHA, Decker MR, Tomko C, Allen ST, Galai N, Sherman SG. Interpersonal and structural factors associated with receptive syringe sharing among a prospective cohort of female sex workers who inject drugs. *Addiction*. 2019; 114(7):1204-1213.
21. Schneider KE, **Park JN**, Allen ST, Weir BW, Sherman SG. Patterns of polysubstance use and overdose among people who inject drugs in Baltimore, Maryland: A latent class analysis. *Drug and Alcohol Dependence*. 2019; 201:71-77.
22. Sherman SG, Morales K, **Park JN**, McKenzie M, Marshall BDL, Green TC. Acceptability of implementing community-based drug checking services for people who use drugs in three United States cities: Baltimore, Boston and Providence. *International Journal of Drug Policy*. 2019; 68:46-53.
23. **Park JN**, Rouhani S, Morales K, Green TC, McKenzie M, Marshall BDL, Allen SA, Sherman SG. Willingness to use safe consumption spaces among opioid users at high risk of fentanyl overdose in Baltimore, Providence, and Boston. *Journal of Urban Health*. 2019; 96(3):353-366.
24. Rouhani S, **Park JN**, Morales KB, Green TC, Sherman SG. Harm reduction measures employed by opioid users with suspected fentanyl exposure in Boston, Baltimore and Providence. *Harm Reduction Journal*. 2019;16(1):39.
25. O'Rourke A, White RH, **Park JN**, Rodriguez K, Kilkenny M, Sherman SG, Allen ST. Acceptability of safe drug consumption spaces among people who inject drugs in rural West Virginia. *Harm Reduction Journal*. 2019; 16(1):51.
26. Lim S, **Park JN**, Kerrigan D, Sherman SG. Severe food Insecurity, Gender-based violence, homelessness, and HIV risk among street-based female sex workers in Baltimore, Maryland. *AIDS Behav*. 2019; 23(11):3058-3063.
27. Morales K, **Park JN**, Glick J, Rouhani S, Green T, Sherman SG. Preference for drugs containing fentanyl from a cross-sectional survey of people who use illicit opioids in three United States cities. *Drug and Alcohol Dependence*. 2019; 204:107547.
28. Bicket M, **Park JN**, Torrie A, Allen S, Weir BW, Sherman SG. Factors associated with chronic pain and non-medical opioid use among people who inject drugs. *Addictive Behaviors*. 2019; 102:106172.
29. **Park JN**, Gaydos CA, White RH, Decker MR, Footer KHA, Galai N, Silberzahn B, Riegger K, Morris M, Huettner SS, Allen ST, Sherman SG. Incidence and predictors of chlamydia, gonorrhea and trichomonas among a prospective cohort of female sex workers in Baltimore, Maryland. *Sexually Transmitted Diseases*. 2019 Dec;46(12):788-794.
30. **Park JN**, Bass JK, Xue QL, Jain KM, Decker MR, Galai N, Footer KHA, Sherman SG. Cumulative violence and PTSD symptom severity among urban street-based female sex workers. *Journal of Interpersonal Violence*. 2021 Nov;36(21-22):10383-10404.

31. Decker MR, **Park JN**, Allen ST, Silberzahn BE, Footer KHA, Huettner S, Galai N, Sherman SG. Inconsistent condom use among female sex workers: Partner-specific influences of substance use, violence, and condom coercion. *AIDS and Behavior*. 2020; 24(3):762-774.
32. Footer KHA, White RH, **Park JN**, Decker MR, Lutnick A, Sherman SG. Entry to sex trade and long-term vulnerabilities of female sex workers who enter the sex trade before the age of eighteen. *Journal of Urban Health*. 2020 Jun;97(3):406-417.
33. Fehrenbacher AE, **Park JN**, Footer KHA, Allen ST, Sherman SG. Exposure to police and client violence among incarcerated female sex workers in Baltimore City, Maryland, 2016-2017. *American Journal of Public Health*. 2020 Jan;110(S1):S152-S159.
34. Schneider KE, O'Rourke A, White RH, **Park JN**, Musci RJ, Kilkenny ME, Sherman SG, Allen ST. Polysubstance use in rural West Virginia: Associations between latent classes of drug use, overdose, and take-home naloxone. *Int J Drug Policy*. 2020 Feb;76:102642.
35. Green TC, **Park JN**, Gilbert M, McKenzie M, Struth E, Lucas R, Clarke W, Sherman SG. A multi-site assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples. *International Journal of Drug Policy*, 2020 Mar;77:102661.
36. Footer KHA, **Park JN**, Rouhani S, Silberzahn B, Huettner S, Allen ST, Galai N, Sherman SG. The development of the Police Practices Scale: Understanding policing approaches towards street-based female sex workers in a U.S. City. *PLoS One*. 2020;15(1):e0227809.
37. Schneider K, Allen, ST, **Park JN**, Weir BW, Sherman SG. Knowledge of Good Samaritan Laws and beliefs about arrests among people who inject drugs a year after policy change in Baltimore, Maryland. *Public Health Reports*. 2020 May/June;135(3):393-400.
38. Rosen G, **Park JN**, Opper N, Lim S, Sherman SG. Patterns and correlates of new drug initiation among female exotic dancers: The contribution of occupational and structural risks. *Substance Use and Misuse*, 2020;55(7):1122-1128.
39. Rouhani S, **Park JN**, Morales K, Green TC, Sherman SG. Trends in opioid initiation in three U.S. cities. *Drug Alcohol Rev*. 2020 May;39(4):375-383.
40. Poteat T, White RH, Footer KHA, **Park JN**, Galai N, Huettner S, Silberzahn BE, Allen ST, Glick J, Beckham SW, Gaydos CA, Sherman SG. Characterising HIV and STIs among transgender female sex workers: a longitudinal analysis. *Sex Transm Infect*. 2021 May;97(3):226-231.
41. Rouhani S, White RH, **Park JN**, Sherman SG. High willingness to use overdose prevention sites among female sex workers (FSW) in Baltimore, Maryland. *Drug and Alcohol Dependence* 2020 Jul 1;212:108042.
42. Silberzahn B, Morris MB, Riegger KE, White RH, Tomko CA, **Park JN**, Footer KHA, Huettner SS, Sherman SG. Barriers and facilitators to retaining a cohort of street-based cisgender female sex workers recruited in Baltimore, Maryland, USA: Results from the SAPPHERE study. *BMC Public Health*. 2020 Apr 29;20(1):585.

43. Mazhnaia, A, O'Rourke A, White RH, **Park JN**, Kilkenny, ME, Sherman SG, Allen ST. Fentanyl preference among people who inject drugs in West Virginia. *Substance Use and Misuse*. 2020; 55(11):1774-1780.
44. Glick J, Lim S, Beckham SW, Tomko C, **Park JN**, Sherman SG. Structural vulnerabilities and HIV risk among sexual minority female sex workers (SM-FSW) by identity and behavior in Baltimore, MD. *Harm Reduction Journal*. 2020 Jun 15;17(1):43.
45. **Park JN**, Tomko C, Silberzahn B, Haney K, Marshall BDL, Sherman SG. A fentanyl test strip intervention to reduce overdose risk among female sex workers who use drugs in Baltimore: Results from a pilot study. *Addict Behav*. 2020;110:106529.
46. Owczarzak J, Weicker N, Urquhart G, Morris M, **Park JN**, Sherman SG. "We know the streets:" Race, place, and the politics of harm reduction. *Health & Place*. 2020; 64:102376.
47. White RH, **Park JN**, Galai N, Decker MR, Allen ST, Footer KHA, Sherman SG. Short-term interruptions to sex work among a prospective cohort of street-based cisgender female sex workers in Baltimore. *International Journal of Drug Policy*. 2020 Aug 5;84:102900.
48. Weicker NP, Owczarzak J, Urquhart G, **Park JN**, Rouhani S, Ling R, Morris M, Sherman SG. Agency in the fentanyl era: exploring the utility of fentanyl test strips in an opaque drug market. *International Journal of Drug Policy*, 2020; 84:102900.
49. Althoff KN, Leifheit KM, **Park JN**, Chandran A, Sherman SG. Opioid-related overdose mortality in the era of fentanyl: Monitoring a shifting epidemic by person, place, and time. *Drug Alcohol Depend*. 2020 Sep 25;216:108321.
50. Decker M, Rouhani S, **Park JN**, Galai N, Footer K, White R, Allen S, Sherman SG. Incidence and predictors of violence from clients, intimate partners and police in a prospective US-based cohort of women in sex work. *Occup Environ Med*. 2020 Nov 3:oemed-2020-106487.
51. Rouhani S, Decker MR, Tomko C, Silberzahn B, Allen ST, **Park JN**, Footer KHA, Sherman SG. Resilience among Cisgender and Transgender Women in Street-Based Sex Work in Baltimore, Maryland. *Womens Health Issues*. 2020 Dec 6:S1049-3867(20)30113-4.
52. Urquhart GJ, Sisson LN, Spira AP, Rojo-Wissar DM, **Park JN**, White RH, Sherman SG. Associations of cumulative violence and structural vulnerability with restless sleep among female sex workers in Baltimore, Maryland. *Sleep Health*. 2020 Nov 19:S2352-7218(20)30254-0.
53. **Park JN**, Rashidi, E, Foti K, Zoorob M, Sherman SG, Alexander GC. Fentanyl and Fentanyl Analogs in the U.S., Illicit Stimulant Supply: Results from National Drug Seizure Data, 2011-2016. *Drug and Alcohol Dependence*, 2020 Nov 23;218:108416.
54. Weicker NP, Whaley S, Urquhart G, **Park JN**, Sherman SG, Owczarzak J. "I Know It Is Going to Ruin Their Life:" Fortune-Telling, Agency, and Harm Reduction in Narratives Concerning Injection Initiation Assistance. *Subst Use Misuse*. 2021;56(12):1860-1868.
55. Tomko C, Nestadt DF, Rouhani S, Silberzahn BE, Haney K, **Park JN**, Galai N, Logie CH, Sherman SG. Confirmatory Factor Analysis and Construct Validity of the Internalized Sex Work Stigma Scale among a Cohort of Cisgender Female Sex Workers in Baltimore, Maryland, United States. *J Sex Res*. 2021 Jul;58(6):713-723.

56. Tomko C, Glick JL, Nestadt DF, White RH, Allen ST, **Park JN**, Galai N, Sherman SG. Characterizing Health Care Access among Cisgender Female Sex Workers with Substance Use Histories in Baltimore, Maryland. *J Health Care Poor Underserved*. 2021;32(3):1584-1603.
57. Sherman SG, Nestadt DF, Silberzahn BE, Decker M, **Park JN**, Footer KHA. The Role of sexually transmitted infections in Police as Clients Among Street-Based Female Sex Workers in Baltimore City. *Sex Transm Dis*. 2021 Jan;48(1):12-18.
58. **Park JN**, Frankel S, Morris M, Dieni O, Fahey-Morrison L, Luta M, Hunt D, Long J, Sherman SG. Evaluation of fentanyl test strip distribution in two Mid-Atlantic syringe services programs. *Int J Drug Policy*. 2021 Mar 10;94:103196.
59. Schneider KE, Urquhart GJ, Rouhani S, **Park JN**, Morris M, Allen ST, Sherman SG. Practical implications of naloxone knowledge among suburban people who use opioids. *Harm Reduct J*. 2021 Apr 28;18(1):47.
60. Latkin C, Dayton LA, Yi G, Konstantopoulos A, **Park J**, Maulsby C, Kong X. COVID-19 vaccine intentions in the United States, a social-ecological framework. *Vaccine*. 2021 Apr 15;39(16):2288-2294.
61. Schneider KE, Nestadt PS, Shaw BR, **Park JN**. Trends in substances involved in polysubstance overdose fatalities in Maryland, USA 2003-2019. *Drug Alcohol Depend*. 2021 Apr 12;223:108700.
62. Zemplak JL, White RH, Nestadt DF, Alexander KA, **Park JN**, Sherman SG. Interpersonal Violence and Contraceptive Method Use by Women Sex Workers. *Womens Health Issues*. 2021 Nov-Dec;31(6):516-522.
63. **Park JN**, Schneider KE, Fowler D, Sherman SG, Mojtabai R, Nestadt PS. Polysubstance Overdose Deaths in the Fentanyl Era: A Latent Class Analysis. *J Addict Med*. 2022 Jan-Feb 01;16(1):49-55.
64. Gandhi P, Rouhani S, **Park JN**, Urquhart GJ, Allen ST, Morales KB, Green TC, Sherman SG. Alternative use of buprenorphine among people who use opioids in three U.S. Cities. *Subst Abuse*. 2021 Jul 2:1-7. doi: 10.1080/08897077.2021.1942395. Epub ahead of print. PMID: 34214403.
65. **Park JN**, Owczarzak J, Urquhart G, Morris M, Weicker NP, Rouhani S, Sherman SG. HIV Risk Among Urban and Suburban People Who Inject Drugs: Elevated Risk Among Fentanyl and Cocaine Injectors in Maryland. *AIDS Behav*. 2021 Jul 21:1-7. doi: 10.1007/s10461-021-03381-y. Epub ahead of print. PMID: 34287755.
66. **Park JN**, Urquhart G, Morris M, Dahal R, Rouhani S, Sherman SG. Discordance Between Self-reported and Biologically Tested Exposure to Fentanyl Among People at Risk of Opioid Overdose. *J Addict Med*. 2022 Feb 4. doi: 10.1097/ADM.0000000000000969. Epub ahead of print. PMID: 35120057.
67. Tomko C, Schneider KE, Rouhani S, Urquhart GJ, **Park JN**, Morris M, Sherman SG. Identifying pathways to recent non-fatal overdose among people who use opioids non-medically: How do psychological pain and unmet mental health need contribute to overdose risk? *Addict Behav*. 2022 Apr;127:107215. doi: 10.1016/j.addbeh.2021.107215. Epub 2021 Dec 20. PMID: 34953432.

68. Rosen JG, **Park JN**, Schneider KE, White RH, Beckham SW, Glick JL, Footer KH, Sherman SG. Mapping Interests in Event-Driven and Long-Acting Pre-exposure Prophylaxis Formulations onto the HIV Risk Environment of Street-Based Female Sex Workers: A Latent Class Analysis. *AIDS and Behavior*. 2022 Apr 1:1-1.
69. Beckham SW, Glick JL, Schneider KE, Allen ST, Shipp L, White RH, **Park JN**, Sherman SG. Latent Classes of Polysubstance Use and Associations with HIV Risk and Structural Vulnerabilities among Cisgender Women Who Engage in Street-Based Transactional Sex in Baltimore City. *Int J Environ Res Public Health*. 2022 Mar 22;19(7):3783. doi: 10.3390/ijerph19073783. PMID: 35409469; PMCID: PMC8997521.
70. Kurani S, Webb L, Cadet K, Ma M, Gibson M, Jallah N, **Park JN**, Johnson RM. Area-level deprivation and adverse childhood experiences among high school students in Maryland. *BMC Public Health*. 2022.
71. Sherman SG, Rouhani S, White RH, Weicker N, Morris M, Schneider K, **Park JN**, Barry C. Acceptability of overdose prevention sites in the business community in Baltimore, Maryland. *J Urban Health*. 2022 May 24. doi: 10.1007/s11524-022-00647-1. Epub ahead of print. PMID: 35610474.
72. Rosen JG*, Zhang L, Pelaez D, Coleman JS, To C, Cooper L, Olatunde PF, Toomre T, Glick JL, **Park JN**. Provider Perspectives on HIV Pre-Exposure Prophylaxis Service Disruptions and Adaptations During the COVID-19 Pandemic in Baltimore, Maryland: A Qualitative Study. *AIDS Patient Care STDS*. 2022 Aug;36(8):313-320. doi: 10.1089/apc.2022.0058. PMID: 35951445.
73. Rosen JG*, Toomre T, To C, Olatunde PF, Cooper L, Glick JL, **Park JN**. Communicative appeals and messaging frames in visual media for HIV pre-exposure prophylaxis promotion to cisgender and transgender women. *Cult Health Sex*. 2022 Sep 8:1-17. Epub ahead of print. PMID: 36074902.
74. **Park JN**, Sherman SG, Sigmund V, Breaud A, Martin K, Clarke WA. Validation of a lateral flow chromatographic immunoassay for the detection of fentanyl in drug samples. *Drug Alcohol Depend*. 2022 Aug 31;240:109610. doi: 10.1016/j.drugalcdep.2022.109610. Epub ahead of print. PMID: 36115223.
75. Rosen JG, Beckham SW, Glick JL, White RH, Park JN, Footer KHA, Sherman SG. Acceptability of Event-Driven and Long-Acting HIV Pre-Exposure Prophylaxis Formulations Among Transgender Women Engaged in Street-Based Sex Work in Baltimore, Maryland. *Transgend Health*. 2024 Apr 3;9(2):185-191. doi: 10.1089/trgh.2022.0057. PMID: 38585249; PMCID: PMC10998007.
76. Amin-Esmaeili M, Gribble A, Johnson RM, Alinsky RH, Oyedele N, Parnham T, Byregowda H, Schneider KE, **Park JN**, Goddard L, Susukida R. Unsolicited Reporting Notifications (URNs) through Maryland's Prescription Drug Monitoring Program (PDMP): Characteristics of Providers. *Drug and Alcohol Dependence Reports*. 2022 Oct 29:100111.
77. Footer, K. H. A., Urquhart, G. J., Silberzahn, B., Rouhani, S., Weicker, N. P., Owczarzak, J., **Park, J. N.**, Morris, M., & Sherman, S. G. (2022). PWUD Experiences of Criminal Justice Reform: Enduring Tensions Between Policing and Harm Reduction in Baltimore, MD. *Contemporary Drug Problems*, 0(0).

78. Rosen JG*, Glick JL, Zhang L, Cooper L, Olatunde PF, Pelaez D, Rouhani S, Sue KL, **Park JN**. Safety in solitude? Competing risks and drivers of solitary drug use among women who inject drugs and implications for overdose detection. *Addiction*. 2022 Dec 5. doi: 10.1111/add.16103. Epub ahead of print. PMID: 36468191.
79. Rosen JG*, Zhang L, Pelaez D, **Park JN**, Glick JL. A Capacity-Strengthening Intervention to Support HIV Pre-exposure Prophylaxis (PrEP) Awareness-Building and Promotion by Frontline Harm Reduction Workers in Baltimore, Maryland: A Mixed Methods Evaluation. *AIDS Behav*. 2023 Jan 3:1–14. Epub ahead of print. Erratum in: *AIDS Behav*. 2023 Feb 1;: PMID: 36596866.
80. **Park JN**, Agee T, McCormick S, Felsher M, Collins K, Hsu J, Schweizer N, Lucas G, Falade-Nwulia O. Retention and Overdose Risk among Patients Receiving Substance Use Disorder Treatment, Mental Health Care and Peer Recovery Support: A Longitudinal Analysis. *J Addict Med*. 2023 Mar 31. Epub ahead of print. PMID: 37000518.
81. Glick JL, Zhang L, Rosen JG, Yaroshevich K, Atiba B, Pelaez D, **Park JN**. A Novel Capacity-Strengthening Intervention for Frontline Harm Reduction Workers to Support Pre-exposure Prophylaxis Awareness-Building and Promotion Among People Who Use Drugs: Formative Research and Intervention Development. *JMIR Form Res*. 2023 Apr 13;7:e42418. PMID: 37052977.
82. Cooper L,* Rosen JG, Zhang L, Pelaez D, Olatunde PF, Owczarzak J, **Park JN**, Glick JL. Exploring the impact of the COVID-19 pandemic on healthcare and substance use service access among women who inject drugs: a qualitative study. *Harm Reduct J*. 2023 Jun 9;20(1):71. doi: 10.1186/s12954-023-00793-y. PMID: 37296423; PMCID: PMC10251329.
83. Byregowda H,* Tomko C, Schneider KE, Russell E, Johnson RM, Susukida R, Rouhani S, Parnham T, **Park JN**. Disruptions to naloxone training among lay and occupational responders in Maryland during the emergence of COVID-19: early impacts, recovery, and lessons learned. *Drug Alcohol Depend Rep*. 2023 Jun 16:100173. Epub ahead of print. PMID: 37362079.
84. Welwean, R.,* Krieg, O., Casey, G., Thompson, E., Fleetham, D., Deering, T., Rosen, J.G., **Park, J.N.** (2023) Evaluating the Impact of Brave Technology Co-op’s Novel Drug Overdose Detection and Response Devices in North America: A Retrospective Study. *Journal of Urban Health*, Oct;100(5):1043-1047. Epub 2023 Sep 5. PMID: 37670172.
85. **Park JN**, Tardif J, Thompson E, Rosen JG, Lira JAS, Green TC. A survey of North American drug checking services operating in 2022. *Int J Drug Policy*. 2023 Oct 3;121:104206. doi: 10.1016/j.drugpo.2023.104206. Epub ahead of print. PMID: 37797571.
86. Rosen JG, Cepeda J, **Park JN**. Demographic patterns and disparities in new HIV diagnoses attributed to injection drug use in the United States. *AIDS*. 2023 Nov 15;37(14):2262-2265. doi: 10.1097/QAD.0000000000003688. Epub 2023 Oct 26. PMID: 37877284.
87. Falade-Nwulia O, Agee T, Kelly SM, **Park JN**, Schwartz S, Hsu J, Schweizer N, Jones J, Keruly J, Shah N, Lesko CR, Lucas GM, Sulkowski M. Implementing a peer-supported, integrated strategy for substance use disorder care in an outpatient infectious disease clinic is associated with improved patient outcomes. *Int J Drug Policy*. 2023 Nov;121:104191. doi: 10.1016/j.drugpo.2023.104191. Epub 2023 Sep 21. PMID: 37740989.

88. Tomko C*, Rouhani S, Johnson RM, Susukida R, Byregowda H, Parnham T, Schneider KE, Gibson M, Heath T, Rickard R, Boyd CE, **Park JN**. Implementation of Overdose Prevention in Maryland: Implications for Resource Allocation, Program Scale-Up, and Evaluation. *Health Promot Pract*. 2023 Nov 22:15248399231209935. doi: 10.1177/15248399231209935. Epub ahead of print. PMID: 37991198.
89. Cepeda JA, Thompson E, Ujeneza M, Tardif J, Walsh T, Morales A, Rosen JG, Green TC, **Park JN**. Costing analysis of a point-of-care drug checking program in Rhode Island. *Drug Alcohol Depend*. 2023 Dec 1;253:111028. doi: 10.1016/j.drugalcdep.2023.111028. Epub 2023 Nov 15. PMID: 38000322.
90. Rosen JG, Thompson E, Tardif J, Collins AB, Marshall BDL, **Park JN**. "Make yourself un-NIMBY-able": stakeholder perspectives on strategies to mobilize public and political support for overdose prevention centers in the United States of America. *Harm Reduct J*. 2024 Feb 15;21(1):40. doi: 10.1186/s12954-024-00955-6. PMID: 38355641.
91. Tan M, Park C, Goldman J, Biello KB, Buxton J, Hadland SE, **Park JN**, Sherman SG, Macmadu A, Marshall BDL. Association between willingness to use an overdose prevention center and probation or parole status among people who use drugs in Rhode Island. *Harm Reduct J*. 2024 Feb 29;21(1):54. doi: 10.1186/s12954-024-00969-0. PMID: 38424553; PMCID: PMC10905878.
92. Lemen PM,* Garrett DP, Thompson E, Aho M, Vasquez C, **Park JN**. High-dose naloxone formulations are not as essential as we thought. *Harm Reduct J*. 2024 May 13;21(1):93. doi: 10.1186/s12954-024-00994-z. PMID: 38741224; PMCID: PMC11089786.
93. Koehm K,* Rosen JG, Yedinak Gray JL, Tardif J, Thompson E, **Park JN**. "Politics Versus Policy": Qualitative Insights on Stigma and Overdose Prevention Center Policymaking in the United States. *Subst Use Addctn J*. 45(4), 682–689. <https://doi.org/10.1177/29767342241253663>
94. Thompson E, Tardif J, Ujeneza M, Badea A, Green TC, McKee H, McKenzie M, **Park JN**. Pilot findings on the real-world performance of xylazine test strips for drug residue testing and the importance of secondary testing methods. *Drug Alcohol Depend Rep*. 2024 May 6;11:100241. doi: 10.1016/j.dadr.2024.100241. PMID: 38808200; PMCID: PMC11131062.
95. Zang X, Skinner A, Krieger MS, Behrends CN, **Park JN**, Green TC, Walley AY, Morgan JR, Linas BP, Yedinak JL, Schackman BR, Marshall BDL. Evaluation of Strategies to Enhance Community-Based Naloxone Distribution Supported by an Opioid Settlement. *JAMA Netw Open*. 2024 May 1;7(5):e2413861. doi: 10.1001/jamanetworkopen.2024.13861. PMID: 38814644; PMCID: PMC11140538.
96. Del Pozo B, **Park JN**, Taylor BG, Wakeman SE, Ducharme L, Pollack HA, Rich JD. Knowledge, Attitudes, and Beliefs About Opioid Use Disorder Treatment in Primary Care. *JAMA Netw Open*. 2024 Jun 3;7(6):e2419094. doi: 10.1001/jamanetworkopen.2024.19094. PMID: 38941101; PMCID: PMC11214109.
97. **Park JN**, Serafini R, Ujeneza M, McKenzie M, Tardif J, Krotulski AJ, Badea A, Grossman ER, Green TC. Xylazine awareness, desire, use and exposure: Preliminary findings from the Rhode Island community-based drug checking cohort study. *Drug Alcohol Depend Rep*. 2024 Jun 5;11:100247. doi: 10.1016/j.dadr.2024.100247. PMID: 38974777; PMCID: PMC11225690.

98. Rouhani S, Luo L, Byregowda H, Weaver N, **Park JN**. Epidemiology of drug arrests in the United States: Evidence from the national survey on drug use and health, 2015-2019. *Prev Med*. 2024 Aug;185:108058. doi: 10.1016/j.ypmed.2024.108058. Epub 2024 Jul 3. PMID: 38969022.
99. Zoorob MJ, **Park JN**, Kral AH, Lambdin BH, Del Pozo B. Drug Decriminalization, Fentanyl, and Fatal Overdoses in Oregon. *JAMA Netw Open*. 2024;7(9):e2431612. Published 2024 Sep 3. doi:10.1001/jamanetworkopen.2024.31612
100. Lim TY, Dong H, Stringfellow E, Hasgul Z, **Park J**, Glos L, Kazemi R, Jalali MS. Temporal and spatial trends of fentanyl co-occurrence in the illicit drug supply in the United States: a serial cross-sectional analysis. *Lancet Reg Health Am*. 2024 Sep 27;39:100898. doi: 10.1016/j.lana.2024.100898. PMID: 39398941; PMCID: PMC11470258.
101. Goldman JE, Park CJ, Trombley J, **Park JN**, Buxton JA, Hadland SE, Macmadu A, Marshall BD. Prevalence and correlates of fentanyl test strip use among people who use drugs in Rhode Island. *Drug Alcohol Depend*. 2024 Nov 1;264:112446. doi: 10.1016/j.drugalcdep.2024.112446. Epub 2024 Sep 12. PMID: 39305808; PMCID: PMC11527559.
102. Tomko C, **Park JN**, Amin-Esmaeili M, Schneider K, Susukida R, Byregowda H, Parnham T, Johnson RM. Combinations of substances contributing to death among overdose decedents in Maryland (2020-2021). *Inj Prev*. 2025 Nov 20;31(6):597-600. doi: 10.1136/ip-2024-045277. PMID: 39798997; PMCID: PMC12246168.
103. Rosen JG, Basta M, St John K, Hallowell BD, Krieger MS, Flavin L, **Park JN**. Time-space characteristics of emergency medical service attendance and layperson naloxone administration during non-fatal opioid overdoses in Rhode Island: A retrospective, event-level analysis. *Ann Epidemiol*. 2025 Mar;103:55-60. doi: 10.1016/j.annepidem.2025.02.009. Epub 2025 Feb 24. PMID: 40010447.
104. Scott L, Davis K, **Park JN**, Majeed S. Evaluating the Sensitivity, Selectivity, and Cross-Reactivity of Lateral Flow Immunoassay Xylazine Test Strips. *J Appl Lab Med*. 2025 Apr 4;jfaf037. doi: 10.1093/jalm/jfaf037. Epub ahead of print. PMID: 40183538.
105. Rosen JG, Olding M, Joshi N, Castellanos S, Valadao E, Hall L, Guzman L, **Park JN**, Knight KR. "It's something we're connected to": Acceptability and adoption of overdose detection technologies implemented in San Francisco permanent supportive housing. *J Subst Use Addict Treat*. 2025 Apr 11:209694. doi: 10.1016/j.josat.2025.209694. Epub ahead of print. PMID: 40222707.
106. Flavin L, Rosen JG, St John K, Hallowell BD, Weidele HR, Krieger MS, McKenzie M, Green TC, Rich JD, **Park JN**. Bystander Presence and Naloxone Administration During Fatal Opioid-involved Overdoses in Rhode Island: Implications for Naloxone Coverage Among Families and Peers. *J Addict Med*. 2026 Jan-Feb 01;20(1):32-37. doi: 10.1097/ADM.0000000000001502. Epub 2025 Apr 25. PMID: 40277214; PMCID: PMC12217843.
107. Rosen JG, Koch R, Aslam R, Riendeau G, Krieger MS, McKenzie M, Ramsey SE, Green TC, Rich JD, **Park JN**. Acceptability and perceived feasibility of restroom motion sensors for overdose detection and response in public bathrooms: A cross-sectional study of businesses and community organizations. *Drug Alcohol Depend*. 2025 Sep 1;274:112788. doi: 10.1016/j.drugalcdep.2025.112788. Epub 2025 Jul 9. PMID: 40651080; PMCID: PMC12335868.

108. Ujeneza M, Tardif J, Thompson E, Badea A, Morales A, Altomare-Jarczyk C, Green TC, Serafinski R, McKenzie M, **Park JN**. Point-Of-Care Drug-Checking: Assessing the Rhode Island Drug Supply Using FTIR Spectroscopy to Detect Fentanyl, Xylazine and Other Substances. *Drug Alcohol Rev.* 2025 Nov;44(7):1866-1874. doi: 10.1111/dar.70037. Epub 2025 Sep 21. PMID: 40977066.
109. **Park JN**, McKee H, Ramsey SE, Rich JD, Green TC, Frank HE, Chatterjee A, Rosen JG. Feasibility and Acceptability of Restroom Motion Sensors for Detecting Overdoses. *Subst Use Addctn J.* 2025 Sep 26:29767342251370822. doi: 10.1177/29767342251370822. Epub ahead of print. PMID: 41006965; PMCID: PMC12859746.
110. Holtgrave DR, Zamboni L, Schady E, Clear A, **Park JN**, McDonald JV. Economic Evaluation of a Naloxone Distribution and Training via a State-Level Opioid Overdose Prevention Program, New York State, April 2023 to March 2025. *J Public Health Manag Pract.* 2026 Mar-Apr 01;32(2):167-169. doi: 10.1097/PHH.0000000000002291. Epub 2025 Oct 23. PMID: 41128501.
111. Figgatt MC, Serafinski RL, Ujeneza M, Turbidez J, McKenzie M, **Park JN**, Grossman ER, Rich J, Green TC. Self-Reported History of Precipitated Withdrawal: A Cross-Sectional Study of People Who Use Unregulated Opioids. *J Addict Med.* 2026 Feb 2. doi: 10.1097/ADM.0000000000001660. Epub ahead of print. PMID: 41622516.
112. Naidu M,* Shin J, St John K, Ledingham EM, McKee H, McKenzie M, **Park JN**. Exploratory Analysis of the Characteristics Associated With the Use of Fentanyl Test Strips Among People Who Use Drugs in Rhode Island, 2021-2023. *Public Health Rep.* 2026 Mar 10:333549261424731. doi: 10.1177/00333549261424731. Epub ahead of print. PMID: 41807276.
113. Rouhani S, Rosen JG, Pozo BD, Figgatt M, Aslam R, Rich JD, Park JN. Business and Service Provider Attitudes Towards Police Involvement in Overdose Response: A Cross-Sectional Survey in Rhode Island Overdose Hotspots. *J Community Health.* 2026 Mar 29. doi: 10.1007/s10900-026-01570-1. Epub ahead of print. PMID: 41904751.

OTHER PEER-REVIEWED PUBLICATIONS: LITERATURE REVIEWS AND COMMENTARIES

114. **Park JN**, Rouhani S, Beletsky L, Vincent L, Saloner B, Sherman SG. Situating the continuum of overdose risk in the social determinants of health: A new conceptual framework. *Milbank Quarterly*, 2020. 98(3):700-746.
115. Jones CM, Bekheet F, **Park JN**, Alexander GC. The evolving overdose epidemic: Synthetic opioids and rising stimulant-related harms. *Epidemiologic Reviews.* 2020 Jan 42(1):154-166.
116. Lombardi AR*, Arya R, Rosen JG, Thompson E, Welwean R, Tardif J, Rich JD, **Park JN**. Overdose Detection Technologies to Reduce Solitary Overdose Deaths: A Literature Review. *International Journal of Environmental Research and Public Health.* 2023; 20(2):1230.
117. **Park JN**, Green TC, Rich JD. Overdose Detection Technologies-A New Frontier in Preventing Solitary Drug Overdose Deaths. *JAMA Psychiatry.* 2023 Apr 26. doi: 10.1001/jamapsychiatry.2023.0546. Epub ahead of print. PMID: 37099309.

118. Harvey LH, Green TC, **Park JN**, Rich JD. Xylazine in the drug supply: A research agenda. *Int J Drug Policy*. 2023 Oct;120:104190. doi: 10.1016/j.drugpo.2023.104190. Epub 2023 Sep 13. PMID: 37708584; PMCID: PMC10664799.
119. Lu A,* Kim C, Rosen JG, Thompson E, Tardif J, Welwean R, **Park JN**. Supervised Inhalation Sites: Preventing Overdose and Reducing Health Inequities among People Who Use Drugs. *Subst Use Misuse*. 2023 Dec 3:1-7. doi: 10.1080/10826084.2023.2287195. Epub ahead of print. PMID: 38044494.
120. Lieberman M, Badea A, Desnoyers C, Hayes K, **Park JN**. An urgent need for community lot testing of lateral flow fentanyl test strips marketed for harm reduction in Northern America. *Harm Reduct J*. 2024 Jun 15;21(1):115. doi: 10.1186/s12954-024-01025-7. PMID: 38877522; PMCID: PMC11179324.
121. Harvey LH, Green TC, **Park JN**, Rich JD. U.S. policy responses to xylazine: Thinking bigger. *Int J Drug Policy*. 2024 Jul 12;130:104517. doi: 10.1016/j.drugpo.2024.104517. Epub ahead of print. PMID: 39003892.

Complete List of Published Work:

<https://www.ncbi.nlm.nih.gov/myncbi/1VA2OqzwwqTAJ/bibliography/public/>

OTHER NON-PEER REVIEWED PUBLICATIONS

1. Safe Solutions to Managing Opioid Use Disorder in the Pandemic and Beyond. April 15, 2021. Public Health Post.
<https://www.publichealthpost.org/research/safe-solutions-to-managing-opioid-use-disorder-in-the-pandemic-and-beyond/>
2. Situating the Continuum of Overdose Risk in the Social Determinants of Health. October 16, 2020. Harvard Medical School, Center for Primary Care.
<http://info.primarycare.hms.harvard.edu/blog/continuum-of-overdose>
3. Hogan should follow Mosby's lead and release older, parole-approved offenders from state prisons. March 20, 2020. The Baltimore Sun.
<https://www.baltimoresun.com/opinion/readers-respond/bs-ed-rr-prisons-coronavirus-letter-20200320-2rgsragxpvht5mtv6k3dujeuwu-story.html>
4. Drug 'safe spaces' deserve support. February 24, 2017. The Baltimore Sun.
<https://www.baltimoresun.com/news/opinion/readersrespond/bs-ed-safe-zones-letter-20170224-story.html>

TECHNICAL AND EVALUATION REPORTS

1. **Park JN**. A comprehensive response to the fentanyl crisis: Strengthening the response to fentanyl through public health interventions (2025). Center for Advancing Health Policy through Research (CAHPR). Providence, Rhode Island. Submitted to U.S. Congress.

2. Zoorob MJ, **Park JN**, Del Pozo B, Kral AH, Lambdin BH. Drug Decriminalization, Fentanyl, and Fatal Overdoses in Oregon (2024). CATO Institute. Washington D.C.
<https://www.cato.org/research-briefs-economic-policy/drug-decriminalization-fentanyl-fatal-overdoses-oregon>
3. *Working group*. Legislative Analysis and Public Policy Association. Model Drug Fentanyl Test Strip and Other Testing Equipment Act (2023), Washington D.C.
<https://legislativeanalysis.org/model-fentanyl-test-strip-and-other-drug-checking-equipment-act/>
4. *Contributor*. Harm Reduction International (2022) Global State of Harm Reduction 2022. London: Harm Reduction International.
5. **Park JN**, Johnson RM, Parnham T, Nuzzo M, Boyd C, Hossain S, Dupree T, Balahmar O, Sealfon N (2022). Leveraging Existing Data for Rapid Response to the Overdose Crisis in Maryland: Assessment of Processes for Data Sharing, Data Acquisition, and Data Use. Maryland Department of Health, Baltimore, Maryland.
6. Schneider KE, Rouhani S, Susukida R, Johnson RM, Parnham T, Sowden S, Byregowda H, Tomko C, Amin-Esmaeili M, Cooper L, **Park JN** (2021). Development of a Model to Optimize Naloxone Saturation in Maryland (Data Brief No. Y2.06.01.V2). Baltimore, MD: Maryland Overdose Data Collaborative
7. Byregowda, H., Schneider, K.E., Tomko C., Rouhani, S., Cooper L., Parnham, T., Susukida, R., Johnson, R., **Park, JN** 2021. Maryland Overdose Data to Action (OD2A) Evaluation Data Brief: Trends in Naloxone Distribution, Training and Impact of COVID-19. Johns Hopkins Bloomberg School of Public Health. Submitted to Maryland Department of Health.
8. Byregowda H, Schneider K, Tomko C, Rouhani S, Cooper L, Parnham T, Susukida R, Amin-Esmaeili M, Johnson RM, **Park JN** (2021). Recommendations for improving the quality of data on naloxone distribution. Data Brief No. Y1.04. Baltimore, MD: Maryland Overdose Data Collaborative.
9. Amin-Esmaeili M, Susukida R, Parnham T, Oyedele N, Sowden S, Byregowda H, **Park JN**, Johnson RM (2021). Unsolicited Reporting Notifications (URNs) from Maryland’s PDMP: Provider and Patient Characteristics (Data Brief No. Y2.08). Baltimore, MD: Maryland Overdose Data Collaborative.
10. Tomko C, Rouhani S, Susukida R, Byregowda H, Parnham T, Amin-Esmaeili M, Schneider KE, Cooper L, **Park JN**, Johnson RM (2021). Overdose Fatalities in Maryland Jurisdictions and Implementation of Overdose Prevention Strategies (Data Brief No.Y2.05). Baltimore, MD: Maryland Overdose Data Collaborative.
11. Falade-Nwulia, O., Agee, T., **Park, J.N.** (2020) John G. Bartlett Specialty Practice Medication Assisted Treatment (MAT) Expansion Report. Johns Hopkins School of Medicine. Submitted to Substance Abuse and Mental Health Services Administration (SAMHSA).
12. **Park, J.N.**, Frankel, S., Dieni, O., Morris, M. Delaware Syringe Services Program Fentanyl Test Strip Pilot: Final Report. (2019) Submitted to the Delaware Department of Health and Social Services, Division of Public Health.

13. Sherman, S.G., Owczarzak, J., **Park, J.N.**, Allen, S.T., Morris, M., Urquhart, G., Mylonas, A., Frankel, S., Woods, C., Pinkerd, N. (2019) Bmore POWER Evaluation. Submitted to Maryland Department of Health and Behavioral Health Systems Baltimore.
14. Sherman, S.G., **Park, J.N.**, Glick, J., McKenzie, M., Morales, K., Christensen, T., Green, T.C. (2018) FORECAST Study Summary Report. Johns Hopkins Bloomberg School of Public Health. Submitted to Bloomberg American Health Initiative.
15. German, D., **Park, J.N.**, Powell, C., Spencer, L. NHBS Baltimore: The BESURE Study 2015 Update. Submitted to the Maryland Department of Health.

CONFERENCE ABSTRACTS (*Mentees)

2025

1. **Park JN**, Figgatt M, Aslam R, Rosen JG, Serafini R, Ujeneza M, McKenzie M, Rich JD, Green TC. Detecting Overdoses in Real-Time to Save Lives: Acceptability and Awareness of Novel Overdose Detection Technologies Among People Who Use Drugs. Poster presentation: College on Problems of Drug Dependence (CPDD). 2026. Portland, OR.
2. Curtis M, Stewart A, Sutherland R, **Park, JN**, Wilson J, Curran J, Petrovic R, Dietze P. Acceptability of overdose helplines among a sample of people who inject drugs in Australia: A cross-sectional exploratory study. Poster presentation: Australasian Professional Society on Alcohol & other Drugs (APSAD). Nov 9-12, 2025. Sydney, Australia.
3. Stadler H, Froias A, Oh C, Holt G, **Park JN**, Rosen JG, Chatterjee A. “Now It Feels like We’re Safe”: Implementation Trajectories of Restroom Reverse-Motion Sensors for Overdose Detection and Response in Massachusetts Homeless Service Settings. Poster presentation: The 49th Annual National Conference of the Association for Multidisciplinary Education and Research in Substance Use and Addition (AMERSA 2025). November 13-15, 2025. Portland, OR.
4. **Aslam R**, Koch R, Riendeau G, Rosen JG, McKenzie M, **Park JN**. Feasibility of restroom monitoring sensors to prevent fatal overdose in Rhode Island. Poster presentation: International Drug Policy Reform Conference. November 12-15, 2025. Detroit MI.
5. **Park JN**, McKee H, Krieg O, Thomas-Sowers C, DeLisle T, Aslam R, Koch R, Rosen JG. Motion sensor systems to prevent overdose: findings from the US Northeast. Oral presentation: Harm Reduction International Conference 2025 (HR25). Bogotá, Colombia. April 29, 2025.
6. Bird J*, Rosen JG, Sanchez Lira JA, Green TC, **Park JN**. Drug checking services in Latin America and the United States: comparing program characteristics and barriers to implementation. Poster presentation. Harm Reduction International Conference 2025 (HR25). Bogotá, Colombia. April 30, 2025.
7. Figgatt MC, Serafini RL, Ujeneza M, Turbidez J, McKenzie M, **Park JN**, Grossman ER, Rich J, Green TC. Opioid agonist treatment and precipitated withdrawal in the age of fentanyl. Oral presentation. Harm Reduction International Conference 2025 (HR25). Bogotá, Colombia. April 30, 2025.

8. Aslam R, McKenzie M, Rosen JG, Froias A, Riendeau R, Krieger M, Ramsey S, **Park JN**. Restroom Motion Sensor Systems to Prevent Overdose: Pilot Findings from Rhode Island. Poster presentation. Boston Medical Center's Together for Hope 2025: Shaping the Future of Addiction Care. April 16-17, 2025. Worcester, MA.
9. Vasquez C, Molina AL, Haidari M, Truong T, Junkin R, Carskadon M, Rich J, McGeary J, **Park JN**. Socioeconomic intersectionality and psychologic comorbidity influences on sleep disruption in patients receiving medications for opioid use disorder (OUD). Poster presentation. Boston Medical Center's Together for Hope 2025: Shaping the Future of Addiction Care. April 16-17, 2025. Worcester, MA.

2024

10. Rosen JG, Basta M, St. John K, Hallowell BD, Krieger MS, Flavin L, Rich JD, **Park JN**. Time-space characteristics of emergency medical service attendance and layperson naloxone administration during non-fatal opioid overdoses in Rhode Island: a retrospective, event-level analysis. The 2024 Symposium on Substance Use Research (SOSUR). Virtual. November 2024.
11. Koch R,* McKenzie, M McKee, H, Aslam R, Vasquez C, Riendeau G, Suero Y, Rosen G, Ramsey S, **Park, JN**. Overdose detection sensors acceptability among commercial and nonprofit organizations in Rhode Island. Symposium on Substance Use Research. November 6-7, 2024. Virtual.
12. Vasquez C,* Molina A, Haidari M, Carskadon M, McGeary J, Ramsey S, Rich JD, **Park JN**. Sleep Disruption in Patients Receiving Medications for Opioid Use Disorder: Does Gender Play a Role? A Review of Literature. Symposium on Substance Use Research. November 6-7, 2024. Virtual.
13. **Park JN**, "Policy Versus Politics: A Mixed-Methods study on Overdose Prevention Center Policymaking in the United States." Poster presentation. National CFAR Meeting. October 29, 2024. New York, NY.
14. **Park JN**, Payer D. "Global Policy Challenges in Implementing Drug Checking Services to Monitor the Unregulated Drug Supply and Promote Health." Oral presentation. International Society for the Study of Drug Policy. June 20, 2024. Montreal, Canada.
15. **Park, JN**, Payer D, Giwa A, Thompson E, Bird J, Arrendondo Sanchez Lira J, Cepeda J, Rosen JG, Green T. "Drug checking approaches to monitoring the illicit drug supply: Evidence, practice, and emerging research." Poster presentation. 2024 NIDA International Forum, June 15, 2024. Montreal, Canada.
16. **Park, JN**, Koch, R., Rosen JG, Thompson E, Tardif J, Vasquez C, McKenzie M, Green TC, Rich JD, Ramsey S. Overdose Detection Technologies for People Who Use Alone. Poster presentation: College on Problems of Drug Dependence (CPDD). Jun 15-19, 2024, Montreal, Canada.
17. Serafinski, R, Ujeneza, M, McKenzie, M, **Park, J.N.**, Grossman, E.R., Green, T.C. Xylazine Knowledge, Use and Exposure in Rhode Island: Preliminary Findings from a Drug Checking Cohort. Poster presentation: College on Problems of Drug Dependence (CPDD). Jun 15-19, 2024, Montreal, Canada.

18. Ujeneza, M, Serafinski, R, McKenzie, M, **Park, J.N.**, Grossman, E.R., Green, T.C. Perceived and detected contents of remnant drug samples from a community drug checking cohort study. Poster presentation: College on Problems of Drug Dependence (CPDD). Jun 15-19, 2024, Montreal, Canada.
19. Murray S, Krieg O, Skarlupka C, **Park, JN.** “Emerging Overdose Detection Technologies for People Who Use Alone.” Panel presentation. Rx and Illicit Drug Summit. Apr 1-4, 2024. Atlanta, Georgia.
20. Rosen JG, Tardif J, Thompson E, Lombardi A, Ramsey S, **Park JN.** “Feasibility and acceptability of fixed-location devices for detecting and responding to solitary drug overdoses in housing and clinical facilities in Rhode Island.” Poster presentation. Together for Hope: Boston Addiction Conference 2024, March 16 2024, Boston, MA.
21. **Park JN**, Koehm K, Tardif J, Thompson E, Yedinak J, Marshall B, Rosen JG. “Politics Versus Policy: Insights from Stakeholders on Stigma and Overdose Prevention Center Policymaking in the United States.” Oral presentation. Together for Hope: Boston Addiction Conference 2024, March 16 2024, Boston MA.
22. Koch R, Tardif J, Vasquez C, Thompson E, Rosen JG, **Park JN.** “Overdose Detection Sensors Acceptability Among Commercial and Nonprofit Organizations in Rhode Island” Oral presentation. Together for Hope: Boston Addiction Conference 2024, March 16 2024, Boston, MA.
23. Thompson E, Bird J, Tardif J, Arredondo Sanchez J, Green T, **Park JN,** “Drug Checking Expansion across the United States and Latin America: An Annual Survey”. Oral presentation. Together for Hope: Boston Addiction Conference 2024, March 16 2024, Boston, MA.

2023

24. Bird J,* Rosen, JG, Thompson E, Arredondo Sanchez J, **Park JN.** Enabling and constraining forces on the operation and implementation of drug checking programs in Latin America: a qualitative study. Poster presentation. Physicians for a National Health Program conference in Atlanta 9 Nov 2023. Online.
25. Tardif, J. “Community Survey Responses to Overdose Detection Technologies: Preliminary Research Findings.” Oral presentation. Symposium on Substance Use Research, 9 Nov 2023, Online.
26. **Park, JN,** Thompson E, Rosen JG, Welwean R, Tardif J, Green TC, Rich JD, Ramsey S. “Overdose Detection Technologies for People Who Use Alone.” Virtual 2023 Symposium on Substance Use Research, 9 Nov. 2023, Virtual.
27. Thompson, E. “Validation of Xylazine Test Strips in a Community Setting.” Virtual 2023 Symposium on Substance Use Research, 9 Nov. 2023, Online.
28. Bird J,* Rosen, JG, **Park JN.** Enabling and constraining forces on the operation and implementation of drug checking programs in Latin America: a qualitative study. Physicians for a National Health Program conference. Nov. 10-12, 2023, Atlanta, GA.

29. **Park JN**, Thompson E, Rosen JG, Welwean R, Tardif J, Green TC, Rich JD, Ramsey S. Overdose Detection Technologies for People Who Use Alone. Oral presentation: AMERSA, Nov 2-4, 2023. Washington D.C.
30. Lim TY, **Park JN**, Dong H, DiGennaro C, Herman T, Zhang Z, Stringfellow EJ, Jalali MS. Is there fentanyl in the stimulant supply? Spatiotemporal evidence from U.S. mortality data. Addiction Health Services Research Conference, 2023, New York, NY.
31. Lim TY, Dong H, Hasgul Z, **Park JN**, Stringfellow EJ, Glos L, Kazemi R, Jalali MS. Temporal and spatial trends of fentanyl co-occurrence in the illicit drug supply in the United States. FDA Controlled Substances Rounds, 2023, Silver Spring, MD.
32. Luo L, Byregowda H, **Park JN**, Rouhani S. Racial/ethnic disparities in drug arrests among people with past year illicit drug use in the United States: Evidence from the NSDUH 2015-2019. American Public Health Association. Nov 12, 2023. Atlanta, GA.
33. Thompson E, Walsh T, Ujeneza M, Tardif J, Badea A, McKee H, Serafinski R, Green TC, **Park JN**. Validation of Rapid Fentanyl and Xylazine Test Strips and FT-IR Spectroscopy for Use in Community Based Settings. Poster presentation: IDeA Symposium, June 1st, 2023. Providence, RI.
34. Koehm K,* Rosen JG, Tardif J, Thompson E, Yedinak J, **Park JN**. Stakeholders' perspectives on the role of stigma in authorizing and implementing safe consumption sites in the United States: a qualitative study. Poster Presentation: Rhode Island Public Health Association Conference. April 14th, 2023. Providence, RI.
35. Russell, E, Schneider K, Gibson M, **Park, JN**. Aggressive Public Policy Approaches to Achieving Naloxone Saturation in Maryland. Poster presentation: National Rx Summit. April 11, 2023; Atlanta, GA.

2022

36. **Park JN**, Mckenzie M, Thompson E, Tardif J, Badea A, Ujeneza M, Mckee H, Serafinski R, Wallace B, Doe-Simkins M, Green TC. Fentanyl test strips and drug checking programs. Oral presentation: Symposium on Substance Use Research. Nov 10, 2022; Virtual.
37. Welwean R,* Krieg, O, Fleetham D, Deering, T, Thompson E, Casey G, **Park JN**. Evaluating the Impact of Brave Technology Coop's Novel Drug Overdose Detection and Response Devices: A Retrospective Analysis. Oral presentation: Symposium on Substance Use Research. Nov 10, 2022; Virtual.
38. Byregowda H, Schneider K, Russell E, Renfro Z, Thompson A, Johnson RM, Tomko C, Parnham, **Park JN**. Centralized naloxone procurement: an interrupted time series analysis of naloxone distribution following the Maryland policy. Oral presentation: Symposium on Substance Use Research. Nov 10, 2022; Virtual.
39. Alinsky R, Amin-Esmaeili M, Susukida R, Parnham T, Oyedele N, Sowden S, Byregowda H, **Park JN**, Johnson RM. Unsolicited Reporting Notifications from Maryland's Prescription Drug Monitoring Program (PDMP): Characteristics of Providers Oral presentation: Association for Medical Education and Research in Substance Abuse (AMERSA). Nov. 6-9, 2022; Boston, MA.

40. **Park JN**, Byregowda H, Amin-Esmaili M, Susukida R, Mitchell C, Lavetsky G, Parnham T, Boyd C, Johnson RM. The Absence of Bystanders: An Investigation of Solitary Drug Overdose Deaths in Maryland, 2021. Oral presentation: American Public Health Association Annual Meeting and Expo. Nov. 6-9, 2022; Boston, MA.
41. Falade-Nwulia O, Agee T, **Park JN**, Kelly S, Schweizer N, Hsu J. RESTORE: A Peer-facilitated model for substance use disorder (SUD) care integration into outpatient infectious disease care. The 10th International Conference on Health and Hepatitis Care in Substance Users. Oral presentation: 19-21 October 2022; Glasgow, Scotland.
42. Rosen JG, Zhang L, Pelaez D, Atiba B, Cooper L, Olatunde PF, Toomre T, **Park JN**, Glick JL. A capacity-strengthening intervention for frontline harm reduction workers to promote HIV pre-exposure prophylaxis (PrEP) among people who inject drugs. Oral presentation: 13th National Harm Reduction Conference. Oct 13-16, 2022. San Juan, Puerto Rico.
43. Krieg O, Hall L, Dixon P, **Park JN**. Love, Experience, and Evidence: The Unhappy Story of Advancing Innovation in Harm Reduction. Oral presentation: 13th National Harm Reduction Conference. Oct 13-16, 2022. San Juan, Puerto Rico.
44. Rosen JG, Zhang L, Pelaez D, Coleman JS, To C, Cooper L, Olatunde PF, Toomre T, Glick JL, **Park JN**. “Falling through the cracks”: provider perspectives on HIV pre-exposure prophylaxis (PrEP) service disruptions and adaptations during the COVID-19 pandemic in Baltimore, Maryland. Poster presentation: 24th International AIDS Conference (AIDS 2022). Jul 29-Aug 2, 2022. Montreal, Canada.
45. Byregowda H., Tomko C., Russell E., Renfro Z., Thomson A., Schneider K., Parnham T., Susukida R., Johnson R.M., **Park J.N.** Impact of COVID-19 pandemic on naloxone distribution and training in Maryland. Oral presentation: 84th Annual Scientific Meeting of the College on Problems of Drug Dependence; June 5-11, 2022; Minneapolis, MN.
46. Johnson R.M., Alinsky R., Amin-Esmaili M., Hossain S., Dunn K., Parnham T., Schneider K., **Park J.N.** Xylazine among Maryland opioid overdose decedents. Oral presentation at the annual meeting of the College on Problems of Drug Dependence. June 5-11, 2022; Minneapolis, MN.
47. Tomko C., Rouhani S., Susukida R., Byregowda H., Parnham T., Amin-Esmaili M., Schneider K., Cooper L., Gibson M., **Park J.N.**, Heath T., Rickard R., Boyd C., Johnson RM. Overdose fatalities in Maryland jurisdictions and implementation of overdose prevention strategies. Poster presentation at the annual meeting of the College on Problems of Drug Dependence. June 5-11, 2022; Minneapolis, MN.
48. Stewart, R.W., Jablonski, L., Clarke, W., Sherman, S.G., **Park, J.N.**, Lepley, D., Hardcastle, V. New Challenge in Substance Use Disorders. Poster session: National Rx Summit; April 18-21, 2022; Atlanta, GA.

2010-2021

49. **Park, J.N.** The Role of Drug Checking and Drug Surveillance in Reducing Drug Related Risks. Oral presentation: Symposium on Substance Use Research. Nov 11, 2021; Virtual.

50. Zhang L,* Rosen JG, Cooper L, Olatunde PF, To C, Toomre T, Pelaez D, Glick JL, **Park JN**. HIV pre-exposure prophylaxis (PrEP) promotion and uptake among cisgender women who inject drugs in Baltimore, Maryland: preliminary formative research findings from the OPAL study. Inter-CFAR HIV and Women Symposium. October 2021. Philadelphia, PA [hosted virtually due to COVID-19].
51. **Park, J.N.**, Owczarzak, J., Morris, M., Urquhart, G., Weicker, N., Rouhani, S., Sherman, S.G. Fentanyl and HIV risk among Urban and Suburban People who Inject Drugs in Maryland. Poster session: AIDS 2020, 6-10 July 2020; Virtual.
52. Rouhani S., **Park J.N.**, Morales K.B, Green T.C., and Sherman S.G. Trends in Opioid Initiation in Boston, Baltimore & Providence. Oral session. American Psychopathological Association Annual Conference, March 5-7, 2020; New York City, NY.
53. **Park, J.N.**, Tomko, C., Silberzahn, B., Marshall, B.D.L., Haney, K., Sherman, S.G. Short-Term Effectiveness of a Brief Fentanyl Test Strip Intervention in Reducing Overdose Risk among Women who Use Street Drugs. Oral Session Presenter and Moderator: The College of Problems of Drug Dependence (CPDD); Jun 15-19, 2019; San Antonio, TX.
54. **Park, J.N.**, Schneider, K, Fowler, D, Mojtabai, R, Nestadt, PS. Drug Overdose Mortality attributable to Polysubstance Use: An Analysis of Medical Examiner Data from 2003-2017. Poster Session: Harm Reduction International conference; Apr 28-May 1, 2019; Porto, Portugal.
55. **Park, J.N.**, Bass, J., Decker, M.R., Sherman, S.G. Cumulative Violence Exposure, Substance Use and PTSD among Street-Based Female Sex Workers in Baltimore, Maryland. Oral session: International Society for Traumatic Stress Studies; 2018 Nov 8; Washington D.C.
56. **Park, J.N.**, McKenzie, M., Sherman, S.G., Green, T.C. Detecting Fentanyl in Street Drugs Using Fentanyl Testing Strips and Portable Machines: Results of a Multi-Site Validation Study. Oral session: the 12th National Harm Reduction Conference; 2018 Oct 18-21; New Orleans, LA.
57. **Park, J.N.**, Morris, M., Silberzahn, B., Allen, S., Footer, K.H.A., Sherman, S.G. Human Rights Violations within Prison Walls: Experiences of Sex Workers in Baltimore City. Oral session: the 12th National Harm Reduction Conference; 2018 Oct 18-21; New Orleans, LA.
58. Gaydos CA, **Park JN**, Footer KHA, Silberzahn B, Holden J, Sherman SG. The Sex Workers and Police Promoting Health in Risky Environments (SAPPHIRE): Results of Prospective Chlamydia, Gonorrhea, and Trichomonas Testing Over One Year. Poster session: STD Prevention Conference; August 27-30, 2018; Washington DC.
59. **Park, J.N.**, Morales, K., McKenzie, M., Green, T.C., Marshall, B., Sherman, S.G. Willingness of People who Use Drugs to Check their Drugs for Fentanyl: A Multisite Study. Poster session: The College of Problems of Drug Dependence (CPDD); 2018 Jun 9-14; San Diego, CA.
60. **Park, J.N.**, Morales, K., Christensen, T., Glick, J., McKenzie, M., Green, T.C., Sherman, S.G. Implementation Considerations in Distributing Fentanyl Test Strips to People at Risk of Opioid Overdose. Poster session: Maryland Harm Reduction Summit; 2018 Jun 28; Baltimore, MD.

61. Glick, J.L., Christensen, T., **Park, J.N.**, McKenzie, M.; Green, T.; Sherman, S. Stakeholder Perspectives on Fentanyl Drug Checking Implementation. Poster session: Maryland Harm Reduction Summit. June 28, 2018; Baltimore, MD.
62. **Park, J.N.**, Allen, S.T., Decker, M.R., Footer, K., Galai, N., Huettner, S., Silberzahn, B., Morris, M., Sherman S.G. Longitudinal Correlates of Non-Fatal Overdose Among Street-Based Female Sex Workers in Baltimore City. Poster session: Society for Epidemiologic Research Meeting; 2018 Jun 19-22; Baltimore, MD.
63. **Park, J.N.**, Raifman, J., Footer, K., Decker, M., Galai, N., Sherman, S.G. PrEP Awareness, Interest and Engagement among Baltimore Female Sex Workers. Poster session: International AIDS Society Conference on HIV Science; 2017 Jun 23-Jul 26; Paris, France.
64. Allen S., **Park J.N.**, Weir B.W., Holtgrave D., Sherman S.G. Effects of Syringe Distribution Policy Change at A Syringe Services Program in Baltimore, MD: A Forecast Analysis. Oral session: International AIDS Society Conference on HIV Science; 2017 Jun 23-Jul 26; Paris, France.
65. Sherman S.G., **Park J.N.**, Silberzahn B., Huettner S., Decker M.R., Galai N., Footer K.H. Police Encounters: A Structural Driver of HIV Risk Behaviors among Street-Based, Cis-Female Sex Workers in Baltimore, Maryland, USA. Poster session: International AIDS Society Conference on HIV Science; 2017 Jun 23-Jul 26; Paris, France.
66. Sherman S.G., Schneider K.E., **Park J.N.**, Allen S.T., Weir B.W. PrEP Interest and Eligibility among People who Inject Drugs in Baltimore, Maryland, USA: A Missed Opportunity for Prevention. Poster session: International AIDS Society Conference on HIV Science; 2017 Jun 23-Jul 26; Paris, France.
67. Allen S., **Park J.N.**, Weir B.W., Holtgrave D., Sherman S.G. Understanding Syringe Distribution Policy Change in Baltimore, MD: Effects on Syringe Distribution and HIV Incidence among People who Inject Drugs. Poster session: The College on Problems of Drug Dependence; 2017 June 17–22; Montreal, Canada.
68. German, D., Shearer, K., **Park, J.N.**, Flynn, C., Latkin, C., Laeyendecker, O., Quinn, T., Clarke, W. Factors Associated with Misreporting HIV Status among MSM from Baltimore. Poster session: Conference on Retroviruses and Opportunistic Infections (CROI); 2016 Feb 22-25; Boston, MA.
69. German, D., Brady, K., Kuo, I., Opoku, J., Flynn, C., Adams, J., Patrick, R., **Park, J.N.** and the Mid-Atlantic CFAR Consortium. Characteristics of African-American men who have sex with men in Baltimore, Philadelphia, and Washington, DC Oral session: National HIV Prevention Conference; 2015 Dec 6-9; Atlanta, GA.
70. **Park, J.N.**, Vail, L., Kirshner, J., Niculescu, A., Lewis D., Welsh, C., Sherman, S. Overdose Education and Naloxone Distribution for Potential Bystanders of Opioid Overdose: A BSHRC Pilot Project in Central Maryland. Oral session: 10th National Harm Reduction Conference; 2014 Oct 23-26; Baltimore, MD.
71. German, D., **Park, J.N.**, Powell, C., Flynn, C. Trends in HIV Prevalence, Injection Behaviors, and Syringe Exchange Utilization Among Baltimore Injection Drug Users. Oral session: 10th National Harm Reduction Conference; 2014 Oct 23-26; Baltimore, MD.

72. **Park, J.N.**, Ogbue, C., Spencer, L., Flynn, C., German, D. Socio-Demographic Correlates of Accessing Needle Exchange Programs among People who Inject Drugs in Baltimore: A Comparison of 2009 and 2012 Data. Poster session: 10th National Harm Reduction Conference; 2014 Oct 23-26; Baltimore, MD.
73. **Park, J.N.**, Ogbue, C., Spencer, L., Flynn, C., German, D. Prevalence of Non-Injection Drug Use, Alcohol Use, and Drug and Alcohol Treatment Utilization in Baltimore City: Comparison of 2010 and 2013 BESURE Data. Poster session: 10th National Harm Reduction Conference; 2014 Oct 23-26; Baltimore, MD.
74. Ogbue, C., Robinson, A., **Park, J.N.**, Flynn, C., German, D. Insurance Status and Related Factors among Injection Drug Users in Baltimore: Implications for Harm Reduction and Healthcare Programs. Poster session: 10th National Harm Reduction Conference; 2014 Oct 23-26; Baltimore, Maryland.
75. **Park, J.N.**, Murray K., Murray, D., Denoe, M., McGrath, C., Post, J., Maher, L. The Impact of a Brief Educational Intervention in Reducing Barriers to Provider-Initiated HIV Testing among Healthcare Providers in Sydney, Australia. Poster session: 20th International AIDS Conference; 2013 Jul 20-25; Melbourne, Australia.
76. **Park, J.N.**, Papworth, E., Moukam, L., Macauley, I.B., Yomb, Y.R., Nkoume, N., Eloundou, J., Lebreton, M., Ketende, S., Grosso, A., Lee, J.A., Baral, S. Optimizing Multicomponent Interventions for Men who have Sex with Men (MSM) in Cameroon: Factors Associated with HIV Testing. Poster session: 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 2013 Jun 30-Jul 3; Kuala Lumpur, Malaysia.
77. Kirschner, J., Pappas, A., **Park, J.N.** Building and Sustaining a Multidisciplinary Student Harm Reduction Coalition. Oral session: 9th National Harm Reduction Conference; 2012 Nov 15-18; Portland, OR.
78. White, B., Dore, G.J., Bates, A., Enriquez, J., Chow, S., **Park, J.N.**, Lloyd, A., Rawlinson, W., Maher, L. High but Declining HCV Incidence in People who Inject Drugs in Sydney, Australia. Oral session: 8th Australasian Viral Hepatitis Conference; 2012 Sep 10-12; Auckland, New Zealand.
79. Bates, A., Enriquez, J., Chow, S., **Park, J.N.**, Maher, L. Engaging and Following up People with Acute Hepatitis C Infection in an Outreach Setting. Poster session: 8th Australasian Viral Hepatitis Conference; 2012 Sep 10-12; Auckland, New Zealand.
80. White, B., Bates, A., Enriquez, J., **Park, J.N.**, Maher, L. Impact of Recruitment Strategy on Retention of People who Inject Drugs in a Longitudinal Study in Sydney, Australia. Poster session: 22nd International Harm Reduction Association Conference; 2011 Apr 3-7; Beirut, Lebanon.
81. White, B., Bates, A., Donald, A., Enriquez, J., Liao, L., **Park, J.N.**, Pham, S., Maher, L. Acceptability and Willingness to Participate in Vaccine Trials among Young People who Inject Drugs in Sydney Australia (on Behalf of the UNSW HCV Vaccine Initiative). Poster session: 18th International AIDS Conference; 2010 Jul 18-23; Vienna, Austria.

82. **Park, J.N.**, Whitwell, B.G., Hermens, D.F., Scott, E.M., Hickie, I.B., Rogers, N.L. Instability of Sleep-Wake Patterns in Young Patients with a Mood Disorder. Poster session: SLEEP. 24th Annual Meeting of the Associated Professional Sleep Societies; 2010 Jun 5-9; San Antonio, TX.

SCHOLARLY WORK PUBLISHED IN OTHER MEDIA

1. Fighting Fentanyl: The FORECAST Study. February 2018. Bloomberg American Health Initiative. <https://americanhealth.jhu.edu/fentanyl>

INVITED PRESENTATIONS

INTERNATIONAL

1. Park J.N., Donaldson K., Clarke W. *The Role of the Clinical Laboratory in Substance Use Treatment and Research*. American Association for Clinical Chemistry Annual Scientific Meeting & Clinical Lab Expo. December 13–17, 2020. Virtual.
2. Park, J.N. *Point-of-Care Drug Checking: Findings from Rhode Island*. British Columbia Centre on Substance Use. June 25, 2024. Vancouver, Canada.
3. Park, J.N. *Overdose Detection Technologies: A New Frontier in Preventing Solitary Drug Overdose Deaths in Communities*. The International Technology Solutions to Prevent Opiate Overdose Network (ITSPON). March 3, 2025. Virtual.
4. Park, J.N. *Fentanyl and Xylazine Test Strips*. Alliance for Collaborative Drug Checking, Summit 2025. May 28, 2025. Virtual.

NATIONAL

1. Green, T., Park J.N., Sherman, S.G. *The FORECAST Study: Initial Results*. Science & Technology Directorate's Opioid Working Group, U.S. Department of Homeland Security. March 5, 2018. Online presentation.
2. Sherman, S.G., Park, J.N. *The Opioid Epidemic and Drug Checking: Rapid Dissemination in the Context of a Crisis*. Drug Policy Alliance Webinar. October 16, 2019.
3. Caldwell J., Slesnick N., Wheelock H., Lucas, D., Park, J.N. *The Continuum of Overdose Risk*. Panel: Harm Reduction. Symposium on Substance Use Research, COBRE on Opioids and Overdose. November 9, 2020. Virtual.
4. Park, J.N. et al. *Experts' Roundtable on Public Safety and Reducing Overdose Among Communities of Color*. Panelist. National Council for Behavioral Health and the Centers for Disease Control and Prevention. February 4, 2021. Virtual.
5. Park, J.N., Li, T., Sferios, E. *Detection of Fentanyl*. Panelist. Alliance for Collaborative Drug Checking Summit. November 3, 2021. Virtual.

6. Park, J.N. *The role of drug checking and drug surveillance in reducing drug related risks*. Oral presentation. 2021 Symposium on Substance Use Research. November 11, 2021. Virtual.
7. Park, J.N. *Fentanyl Test Strips and Other Drug Checking Methods: Understanding the Perspectives of the Harm Reduction Community (Roundtable)*. The Reagan-Udall Foundation for the Food and Drug Administration. October 21, 2022. Virtual.
8. Park, J.N. *Model Fentanyl Test Strip and Other Drug Checking Laws*. Model Law Virtual Knowledge Labs. White House Office of National Drug Control Policy. June 8, 2023. Virtual.
9. Brothers, S., Park, J.N., Walley, A. *Envisioning a National Research Agenda for Harm Reduction: Approaches for Optimizing Research and Implementation of Harm Reduction Services*. National Academy of Sciences, Engineering and Medicine Workshop. January 31, 2024. Virtual.
10. Park, J.N. *Innovations in Overdose Detection Technologies*. MIT Innovation Fellows. April 22, 2024. Virtual.
11. Park J.N. *Implementing a peer-supported, integrated strategy for substance use disorder care in an outpatient infectious disease clinic is associated with improved patient outcomes*. American Society of Addiction Medicine. October 17, 2024. Baltimore City, Maryland.
12. Park J.N. Krieg O. *Overdose Detection Technologies*. Centers for Disease Control and Prevention National Center for Injury Prevention and Control. October 31, 2024. Virtual.
13. Park J.N. *Overdose Detection Technologies: A New Frontier in Preventing Solitary Drug Overdose Deaths in Communities*. Drug Policy Alliance. May 28, 2025. Virtual.

REGIONAL

1. Park, J.N., Allen S., Weir, B., Sherman, S. *Assessment of Syringe Coverage among Baltimore Syringe Exchange Program Clients: Preliminary Findings*. Baltimore City Health Department. July 13, 2016. Baltimore, Maryland.
2. Park, J.N. *Let's Talk about Fentanyl*. Bmore Power Hackathon, Johns Hopkins Communication Programs. January 31, 2018. Baltimore, Maryland
3. Park, J.N., Green, T., Sherman, S.G. *The FORECAST Study: Initial Results*. Maryland Department of Health, Drug User Working Group. May 21, 2018. Baltimore, Maryland.
4. Park, J.N., Silberzahn, B. *Building Relationships Through Harm Reduction: Fentanyl Testing as Overdose Prevention*. Delaware Department of Health and Social Services, Division of Public Health. August 21, 2018. Dover, Delaware.
5. Park, J.N., Sherman, S.G. *Harm Reduction Approaches to the Opioid Epidemic: Innovation and Evidence*. Maryland-DC Society of Addiction Medicine Annual Meeting and Conference. September 22, 2018. Clarksville, Maryland.
6. Park, J.N. *Addressing the Fentanyl Epidemic: Innovation and Evidence*. Health Advisory Board Meeting, Johns Hopkins University. October 12, 2018. Baltimore, Maryland.

7. Park, J.N., Sherman, S.G. *Fentanyl Test Strips: A Strategy to Promote Safety in the Community*. Maryland Harm Reduction Training Institute Webinar, Maryland Department of Health. February 5, 2019.
8. Park, J.N. *Structural risks: Police Encounters and Health Behaviors*. Maryland Department of Health. July 31, 2019. Baltimore, Maryland.
9. Park, J.N. et al. *The Opioid Crisis – Future of Health Policy*. Panelist. The Mid-Atlantic Public Health Conference. January 14, 2021. Virtual.
10. Park, J.N. *Mitigating the risks associated with illicit fentanyl use*. Session: Emerging Research on Addiction and Overdose, Virtual North East Regional IDEa Conference (v-NERIC). August 18, 2021. Virtual.
11. Park, J.N. *Reducing the risks associated with fentanyl use in Vermont*. Community Stat Meeting. September 23, 2021. Burlington, Vermont. Virtual.
12. Park, J.N. *Introducing the Harm Reduction Innovation Lab*. COBRE on Opioids and Overdose Lecture Series. April 25, 2022. Providence, Rhode Island. Virtual.
13. Park, J.N. *Maryland Overdose Data to Action (OD2A): Naloxone Program Evaluation*. Maryland Department of Health, Overdose Data to Action Surveillance Meeting. July 18, 2022. Virtual.
14. Park, J.N. *Naloxone Program Evaluation*. Maryland Behavioral Health Administration. August 2, 2022. Baltimore, Maryland. Virtual.
15. Park, J.N. *Maryland Overdose Data to Action (OD2A): Streamlining Data Integration and Access*. Maryland Department of Health, Overdose Data to Action Surveillance Meeting. December 27, 2022. Baltimore, Maryland. Virtual.
16. Park, J.N. *Innovations in Harm Reduction Research to Address Comorbidities*. Johns Hopkins University Center for AIDS Research. January 4, 2023. Baltimore, Maryland. Virtual.
17. Park, J.N., Agee T. *Increasing Access to Naloxone in Anne Arundel County: Latest Developments in Research and Practice*. Grand Rounds, Anne Arundel Medical Center. January 12, 2023. Anne Arundel County, Maryland. Virtual.
18. Park, J.N. *COBRE Drug Checking Pilot Project – Community Forum*. July 6, 2023. Pawtucket, Rhode Island.
19. Park, J.N. *Introduction to Drug Policy and Harm Reduction*. HRSA Integrated Substance Use Disorder Training Program. Thundermist. November 2023. Woonsocket, Rhode Island. Virtual.
20. Park, J.N., Thompson E. *Update to Brave and PONI RI Pilot Project 2022–2023*. December 2023. Virtual.
21. Atiba B., Gaddis A., Park, J.N. *Overdose Prevention Centers*. Charm City Care Connection. February 6, 2024. Baltimore, Maryland.
22. Park, J.N. *Innovations in Harm Reduction: Research from Rhode Island*. MedStar Department of Surgery Grand Rounds. May 3, 2024. Baltimore, Maryland.

23. Park, J.N. *Overdose Detection Technologies for People Who Use Alone: Findings from the Rhode Island Pilot Study*. Rhode Island EOHHS. May 16, 2024. Virtual.

MEDIA APPEARANCES

Trump signs bill with harsher penalties for dealers of fentanyl variants. Washington Post. July 16, 2025.
<https://www.washingtonpost.com/politics/2025/07/16/trump-halt-act-fentanyl-bill/>

Test Strips Do Tell You If Xylazine Is Present, But Prone to False Positives. Filter. May 1, 2025.
<https://filtermag.org/xylazine-test-strips-accuracy/>

Fatal overdoses often happen when users are alone. Hotlines, sensors can save lives. Washington Post. October 19, 2024.
<https://www.washingtonpost.com/health/2024/10/19/fatal-drug-overdoses-alarms-sensors/>

Fatal overdoses killing more Oregonians as national figure drops. The Lund Report. October 1, 2024.
<https://www.thelundreport.org/content/fatal-overdoses-killing-more-oregonians-national-figure-drops>

Emerging Overdose Detection Technologies and Hotlines. Harm Reduction: Compassionate Care for People Who Use Drugs. AMERSA podcast, August 29, 2024.
<https://amersa.org/amersa-podcast/>

How a friend's death turned Colorado teens into anti-overdose activists. Kaiser Family Foundation Health News. February 29, 2024.
<https://www.cnn.com/2024/02/29/health/colorado-student-naloxone-kff-health-news-partner>

Fentanyl test strips could save lives. Why are they still illegal in Texas? The Dallas Morning News. September 21, 2023.
<https://www.dallasnews.com/news/politics/2023/09/21/fentanyl-test-strips-effectively-detect-the-drug-why-are-they-still-illegal-in-texas/>

Opioid Settlement Funds. WFYI/Side Effects Public Media Radio, Indianapolis. August 2, 2023.
<https://www.wfyi.org/news/articles/indiana-is-getting-507-million-in-opioid-settlement-money-heres-how-it-will-be-handled>

'Just trying to help him stay alive' Chicago Reader. July 24, 2023.

<https://chicagoreader.com/news-politics/overdose-harm-reduction-funding-prevention-government/>

When naloxone isn't enough: How technology can save lives when people use drugs alone. News from Brown. May 2, 2023. <https://www.brown.edu/news/2023-05-02/overdose-detection-technologies>

Fentanyl test strips help prevent overdoses, why are they still controversial? STATNews. December 19, 2022.

<https://www.statnews.com/2022/12/19/fentanyl-test-strips-help-prevent-overdoses-why-are-they-still-controversial/>

The US needs more structural interventions to address the effects of systemic racism in HIV. NAM AIDSMap. December 14, 2022.

<https://www.aidsmap.com/news/dec-2022/us-needs-more-structural-interventions-address-effects-systemic-racism-hiv>

A Long-Awaited Harm Reduction Gathering in Puerto Rico. Filter. November 8, 2022.

<https://filtermag.org/harm-reduction-conference-puerto-rico/>

Fentanyl Test Strips Highlight Rift in Nation's Struggle to Combat Drug Deaths. New York Times. October 1, 2022. <https://www.nytimes.com/2022/10/01/health/fentanyl-test-strips.html>

Overdose Prevention Sites. The Addiction Recovery Channel, Vermont. October 7, 2021.

<https://www.cctv.org/watch-tv/programs/overdose-prevention-site-protecting-lives-people-who-use-drugs> (video link: <https://m.youtube.com/watch?v=i3myCVPciyw>)

Fentanyl has killed thousands in Michigan. This is one family's story. Fox 47 News. May 3, 2021.

<https://www.fox47news.com/news/fentanyl-has-killed-thousands-in-michigan-this-is-one-family-s-story>.

Research News Brief: Researchers Propose New Framework to Address the Opioid Epidemic's Social Roots, Decrease Drug-Related Deaths. August 24, 2020. Johns Hopkins Bloomberg School of Public Health.

5 things to know about overdose prevention sites. Fall 2019 issue. Johns Hopkins Bloomberg Public Health Magazine.

Safe injection sites. July 10, 2019. Edmonton Radio.

Study asks if high-risk opioid users if they'd take advantage of safe consumption sites. July 2, 2019. The Hub, Johns Hopkins University.

Hopkins study: Overdose prevention sites would be used. June 21, 2019. The Daily Record.

<https://thedailyrecord.com/2019/06/21/hopkins-study-overdose-prevention-sites-would-be-used/>

Safe consumption spaces would be welcomed by high-risk opioid users. Eureka Alert AAAS News Release. June 5, 2019.

Is this the answer to safer heroin? January 16, 2019. The Stream, Al Jazeera.

<https://www.aljazeera.com/program/the-stream/2019/1/16/is-this-the-answer-to-safer-heroin>

How drug checking could prevent fentanyl overdoses. Summer 2018 issue. Johns Hopkins Bloomberg Public Health Magazine.

GRANTS

ACTIVE

- 1. Feasibility and Acceptability of Technology-Assisted Overdose Response Interventions in Rhode Island*
P20GM125507 (Rich) 5/1/23 - 4/30/27
NIH/NIGMS
Role: Contact PI, Research Project Leader
- 2. The impact of a technology-assisted overdose intervention for clinical and community settings*
Patterson Trust Mentored Research Award (Park) 1/31/24 - 1/30/27
Robert E. Leet and Clara Guthrie Patterson Trust
Role: PI
- 3. Development and Evaluation of a Mobile Health Intervention for Co-Morbid Opioid Use Disorder and Posttraumatic Stress Disorder During Community Re-entry*
R61DA061335 (Weiss) 9/15/24 - 6/30/30
NIH/NIDA
Role: Co-I
- 4. Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD*
R01DA059469 (Carkadon, McGeary, Rich) 9/21/23 - 9/20/27
NIH/NIDA
Role: Co-I
- 5. Navigating the Fentanyl Age with Community Drug Checking*
UG3DA056881 (Green) 07/01/22 – 06/31/27
NIH/NIDA
Role: Co-I
- 6. Department of Medicine Recruitment Grant*
Internal Funds 09/01/22 -
Warren Alpert Medical School, Brown University
Role: PI

PENDING

- 1. Leveraging Regional Drug Checking Data to Uncover Drug Supply, Overdose, and Drug Treatment Dynamics*
1R01DA065941 (Park, Green) 4/1/26-3/31/31
NIH/NIDA
Role: MPI
- 2. NaxoScan Mobile App Toolkit: Supporting Successful Use of Drug Test Strips by Anyone Anywhere*

1R42 DA066412 (Cogdell) 4/1/26-3/31/30
NIH/NIDA
Role: Co-I

3. *A Mobile App Based Intervention to Respond to Overdoses in Real Time*
Rhode Island Medical Foundation 6/1/26-5/30/27
Role: PI

COMPLETED

1. *Salary Support*
Faculty Assessment Grant (Park) 10/1/23 - 9/30/24
Brown Physicians Inc.
Role: PI
2. *Implementation Science Research on Supervised Injection Facilities in Rhode Island*
P30AI042853 (Cu-Uvin) 07/01/22-06/31/23
NIH/NIAID
Role: Pilot Project PI
3. *Evaluation Services for the Maryland Overdose Data to Action Project (MD OD2A):
Outcome Monitoring & Quality Improvement*
6NU17CE924961/BPM020865 (Park & Johnson) 12/01/20-06/30/23
CDC/MDH
Role: Co-PI
4. *Feasibility and Evaluation of a Novel Drug Checking Program in Rhode Island*
P20GM125507 (Rich) 07/01/22-04/30/23
NIH/NIGMS
Role: Pilot Project PI
5. *COBRE Center on Opioids and Overdose-Recruitment Grant*
P20GM125507 (Rich) 09/01/21-08/31/22
NIH/NIGMS
Role: Project PI
6. *Department of Medicine Opiate Funding for Grant Writing*
Internal Funds (Rice) 10/01/22-11/15/22
Warren Alpert Medical School, Brown University
Role: PI
7. *Improving HIV Pre-Exposure Prophylaxis Engagement among High-Risk Women in
Baltimore*
P30AI094189 (Chaisson/Beyrer) 08/01/20-07/31/21
NIH/NIAID/Ending the HIV Epidemic Supplement
Role: Project PI
8. *John G. Bartlett Specialty Practice Medication Assisted Treatment (MAT) Expansion*

- H79TI081639 (Falade-Nwulia) 9/17/18-8/27/21
 SAMHSA
 Role: Grant Evaluator
9. *Peer-Based Outreach Evaluation: The PROMOTE Study*
 AS019-HRO-JHPH (Sherman) 01/01/18-12/31/20
 BHSB/MDH
 Role: Co-I
10. *Assessing the Role of Fentanyl in Shaping HIV Risk among People Who Inject Drugs*
 P30AI094189 (Chaisson/Beyrer) 05/02/19 – 04/30/21
 NIH/NIAID
 Role: Pilot Project PI
11. *Psychosocial Determinants of Adolescent Opioid Use in Maryland*
 Spark Award (Johnson) 05/02/19 – 04/30/21
 Bloomberg Philanthropies
 Role: Co-I
12. *Implementation and effectiveness of a community-based drug checking unit in Baltimore City*
 Abell Foundation (Sherman) 9/1/20 – 12/31/21
 Program Grant
 Role: Co-I
13. *Examining business support of overdose prevention sites*
 Spark Award (Sherman) 7/1/19 - 6/30/2020
 Bloomberg Philanthropies
 Role: Co-I
14. *Delaware Fentanyl Test Strip Program Evaluation*
 Program Evaluation Grant (Park) 12/1/18 - 05/31/19
 BCCS/DHSS
 Role: PI
15. *Baltimore City Needle Exchange Fentanyl Test Strip Evaluation*
 Program Evaluation Grant (Sherman) 07/01/18 - 06/30/19
 BCHD
 Role: Co-I
16. *A Structural HIV Prevention Intervention Targeting High-Risk Women*
 R01DA041243 (Sherman) 07/01/18 - 05/31/19
 NIH/NIMH
 Role: Co-I
17. *The Fentanyl Overdose Reduction Checking Analysis Study (FORECAST)*
 Vanguard Award (Sherman) 02/01/17 - 12/15/17

Bloomberg Philanthropies
Role: Study Director

18. *Evaluation of Needle Exchange Distribution Policy*
AmFAR Foundation (Sherman) 02/1/16 - 01/31/17
Role: Project Manager
19. *The HIV Risk Environment of High-Risk Women: Interaction with Public Safety*
R01DA038499 (Sherman) 02/01/15 - 11/30/18
NIH/NIDA
Role: Data Analyst
20. *National HIV Behavioral Surveillance System*
5U1BPS003259-03 (Flynn & German) 06/01/13 – 12/31/15
CDC/MDH/JHU
Role: Data Analyst

UNIVERSITY TEACHING, ADVISING and MENTORING ROLES

CLASSROOM INSTRUCTION

- 2021 Scientific Writing in Health Sciences: Developing A Manuscript for Publication I, JHBSPPH
- 2021 Scientific Writing in Health Sciences: Developing A Manuscript for Publication II, JHBSPPH
- 2016 Section Instructor, Fundamentals of Epidemiology, Department of Epidemiology, JHBSPPH.

INVITED LECTURES

- 2026 Technologies to Detect and Respond to Overdoses in Real-Time. Department of Psychological Sciences and Missouri Institute of Mental Health (UMSL-MIMH), Addiction Science. University of Missouri St. Louis.
- 2022-2025 Innovations in Harm Reduction Research, Practice and Policy. Epidemiology in Evidence-Based Policy. Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University.
- 2022 Harm Reduction Approaches to Public Health. College of Health Solutions. Arizona State University.
- 2020-2021 Harm Reduction: A Social Justice Approach to Health. Substance Use: a Public Health Perspective, Department of Epidemiology, University of Colorado School of Public Health.
- 2021 Harm Reduction and Overdose Prevention. Graduate Seminar in Injury Research and Policy, Department of Health, Policy and Management, Bloomberg School of Public Health, Johns Hopkins University.

GUEST LECTURES

- 2026 Overdose and Drug Checking Technologies. Harm Reduction as Public Health. Department of Epidemiology, School of Public Health, Brown University.
- 2025 Manuscripts and Peer Review. General Internal Medicine Residency Research Track Seminar, Alpert Medical School, Brown University.
- 2024-2025 Developing a Research Plan. General Internal Medicine Intern Research Retreat. Alpert Medical School, Brown University.
- 2024-2025 Innovations in Harm Reduction Research, Practice and Policy. Addiction Medicine Fellowship, Alpert Medical School, Brown University.
- 2023-2024 The History of Harm Reduction and Drug Policy. Pre-clinical medical student elective, Alpert Medical School, Brown University.
- 2023 The Future of Harm Reduction and Drug Policy in the United States. Addiction Medicine Fellowship, Alpert Medical School, Brown University.
- 2021 Harm Reduction Response to the Opioid Epidemic: Innovation and Evidence. Epidemiology in Evidence-Based Policy. Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University.
- 2020 Harm Reduction Responses to the Opioid Epidemic: Data and Politics. Epidemiology in Evidence-Based Policy. Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University.
- 2020 Harm reduction in the era of synthetics. Public Health Perspectives On U.S. Drug Policy, Department of Health, Policy and Management, Bloomberg School of Public Health, Johns Hopkins University.
- 2019-2021 Harm Reduction. The Epidemiology of Substance Use and Related Problems, Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University.
- 2019 Gender, Power and Infectious Disease Risk. Foundations of Social Epidemiology, Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University.
- 2018, 2019 Opioid Epidemic Awareness and Education Program. Fall Graduate Student Orientation, Bloomberg School of Public Health, Johns Hopkins University.
- 2018 Harm Reduction in Action: Program Evaluation to Epidemiology. Introduction to Harm Reduction. Johns Hopkins University.
- 2018 HIV and Trauma: Biology to Structure. Fundamentals of Health, Behavior and Society. Department of Health, Behavior and Society, Bloomberg School of Public Health, Johns Hopkins University.
- 2018 Non-Probability Sampling. Health Survey Research Methods. Summer Institute, Bloomberg School of Public Health, Johns Hopkins University.
- 2018 Sex Workers and Baltimore City: An untold story. Community Based Learning - Practicum Community Health Care. Johns Hopkins University.

- 2017 Sex workers in Baltimore: An Untold Story. Generation Tomorrow, Center for AIDS Research, Bloomberg School of Public Health, Johns Hopkins University.
- 2016-2018 Quality Assurance and Quality Control. Health Survey Research Methods. Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University.
- 2016 Sex, drugs and HIV. Fundamentals of Epidemiology, Johns Hopkins University.

TEACHING ASSISTANT

- 2012 Principles of Epidemiology, Department of Epidemiology, JHBSPH
- 2012 Epidemiology and Public Impact of HIV/AIDS, Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University.
- 2012 Advanced Topics on Control and Prevention of HIV/AIDS, Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University.
- 2012 Epidemiology and Natural History of Human Viral Infections, Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University.

ADVISEES

- 2026- Christina Vasquez, MD candidate, Brown University, Alpert Medical School
- 2025- Filbert Aung, MD candidate, Brown University, Alpert Medical School
- 2024- Autumn Froias, PhD candidate, Simmons University, School of Social Work
- 2023-2026 John Bird, MD candidate, Brown University, Alpert Medical School
- 2024-2025 Menaka Naidu, MPH candidate, Brown University, School of Public Health
- 2023-2024 Katherine Dowling, MPH candidate, Brown University, School of Public Health
- 2022-2023 Ralph Welwean, PhD candidate, Department of Epidemiology, School of Public Health, Brown University
- 2022 Kristin Koehm, MPH candidate, Brown University, School of Public Health
- 2022 Lina Modjarrad, MPH candidate, Brown University, School of Public Health
- 2020-2023 Lou-Anne Chichester, DrPH candidate (Co-Advisor), JHBSPH
- 2021 Shatabdi Patel, MPH (Co-Advisor), JHBSPH
- 2020-2021 Leanne Zhang, MSPH, JHBSPH
- 2019-2020 Tzu-Miao Pu, MPH, JHBSPH
- 2018-2019 Sarah Mixson, MPH, JHBSPH
- 2018-2019 Sari Frankel, MPH, JHBSPH

PRELIMINARY ORAL PARTICIPATION

- 2021 Joseph Rosen, PhD, Department of International Health (Alternate), JHBSPH

2019 Sherri-Channell Brighthaupt, PhD, Department of Mental Health, JHBSPH

THESIS READER

2024 Jocelyn Yang, BS candidate, Brown University
2023 Lina Modjarrad, MPH candidate, Brown University, School of Public Health
2021 Ming Sun, MHS, Department of Health, Behavior and Society, JHBSPH
2020 Lena Jewler, MHS, Department of Health, Behavior and Society, JHBSPH

PRACTICUM/INTERNSHIP/STUDENT RAASHIP SUPERVISOR

2025 Kenneth Kalu, Brown University
2025 Gabrielle Riendeau, Massachusetts College of Pharmacy and Health Sciences
2024 Amanda Molina, Brown University
2024 Masoumeh Haidari, Brown University
2022-2024 Alexa Lombardi, Boston College
2022-2024 Ritikraj Arya, Brown University
2022-2024 Alison Lu, Brown University
2022-2024 Claire Kim, Brown University
2023 Rahmla Jones, Brown University
2023 Jocelyn Yang, Brown University
2023 Megan Aho, Brown University
2023 Joel Gonzalez, Brown University
2022-2023 Ralph Welwean, Brown University
2022-2023 Orly Richter, Brown University
2022 Isabella Steidley, Brown University
2022 Naile Ozpolat, Brown University
2022 Caleb Ellis, Brown University
2021 Praise Olatunde, Department of International Health, JHBSPH
2021 Lyra Cooper, MHS, Department of Health, Behavior and Society, JHBSPH
2021 C To, MSPH, Department of Health Policy and Management, JHBSPH
2021 Teagan Toome, BA, Johns Hopkins University
2020-2021 Leanne Zhang, MHS, Department of International Health, JHBSPH
2018 Adam Moreno-Mendelson, NIDA Post-Baccalaureate Fellow
2017 Anyu Xue, Johns Hopkins University

PUBLIC HEALTH PRACTICE

Letter to Congress. Vital Substance Use and Mental Health Services at Risk: Save SAMHSA, the CDC, and HRSA (5/12/25)

Written Testimony, House Bill 1096, Public Health – Overdose and Infectious Disease Prevention Services Program. Maryland Health and Government Operations Committee (2/28/24)

Written Testimony, House Bill 706, Criminal Law - Drug Paraphernalia for Administration – Decriminalization. Maryland House Judiciary Committee (2/9/24)

Oral Testimony, Senate Bill 1015, Amendment to the Uniform Controlled Substances Act. Rhode Island Senate Judiciary Committee (6/1/23)

Oral Testimony, House Bill 7896, Amendment to the Uniform Controlled Substances Act. Rhode Island House Judiciary Committee (4/19/23)

Written Testimony, House Bill 6162, Amendment to the Uniform Controlled Substances Act. Rhode Island House Judiciary Committee (4/19/23)

Written Testimony, Senate Bill 394, Statewide Targeted Overdose Prevention (STOP) Act of 2022. Maryland Senate Finance Committee (02/16/22)

Written Affidavit. COVID-19 Risks for Detained Populations in Maryland from a group of concerned scientists, physicians, and public health experts to the Maryland Legislature (03/16/20)

Oral Testimony, Senate Bill 990, Public Health - Overdose and Infectious Disease Prevention Services Program. Maryland Senate Finance Committee (03/10/20)

Oral Testimony, House Bill 720, Criminal Law - Drug Paraphernalia for Administration – Decriminalization. Maryland House Judiciary Committee (02/18/20)

CERTIFICATIONS

- 2023 Advance RI-CTR Mentoring Training Program, Rhode Island
- 2013 Maryland HIV Counseling & Testing Skills Level I, University of Maryland
- 2013 Certificate in Public Health, National Board of Public Health Examiners
- 2013 Overdose Prevention & Response Training, Baltimore City Health Department
- 2010 HIV/Hepatitis Counseling, Albion Centre, Sydney, Australia
- 2010 Phlebotomy training, Pathology Foundation, Sydney, Australia
- 2009 Workplace First Aid, Australian Red Cross, Sydney, Australia

COMMUNITY SERVICE

- 2023- Advisory Council, Charm City Care Connection, Baltimore, MD

- 2022- Founding Member, Overdose Technology Consortium, North America
- 2017 Volunteer Student Epidemiologist, Surveillance and Outbreak Response Team (SORT), Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
- 2014-2015 Program Coordinator, Overdose Education and Naloxone Distribution program, Baltimore Harm Reduction Coalition, Baltimore, Maryland
- 2011-2013 Events Chair, Baltimore Harm Reduction Coalition, Baltimore, Maryland
- 2012 Community Advisory Board, Connect 2 Protect, Baltimore, Maryland
- 2008-2009 Drug and Alcohol Case Manager, Drug-ARM, Sydney, Australia